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Pancreatic cancer (PC) is one of the most lethal malignancies, and since 53% of 
patients are diagnosed with the advanced metastatic stage of the disease, 
handling/targeting this aggressive metastatic cancer becomes a challenge. The present 
therapy for PC includes gemcitabine, Abraxane, erlotinib, FOLFIRINOX, and their 
combinations. All of these therapies along with surgical interventions have so far 
increased the average five-year survival for PC patients to 7.2%. One of the chief 
contributors for this dismal prognosis of pancreatic cancer is cancer stem cell (CSC) 
population, which are responsible for the aggressive and refractory nature of the 
disease. CSCs are a small subpopulation in the tumor, which are held accountable for 
early metastasis, drug resistance and disease relapse in different cancers including PC 
[1-3]. Cancer stem cells (CSC) are primary culprits for aggressive metastatic nature of 
pancreatic cancer, and present therapies fail to target CSC. EGFR family of proteins is 
vital for CSC self-renewal and maintenance and necessary for PC initiation and 
progression. In this thesis, we aim to develop a targeted therapy for pancreatic cancer 
by targeting cancer stem cell population thereby decreasing the metastasis. 
In the first part of this thesis, we utilize tissue murine and human origin to develop three-
dimensional organoids to be able to evaluate therapy response in them. We show that 
we successfully generate organoids for mouse pancreatic cancer, normal pancreas, 
human PDAC samples, and mouse prostate and lungs. We engage PDAC organoids for 
further studies and show retention and expansion of different subsets of cancer stem cell 
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population in these organoids. We also standardize a method to evaluate growth and 
inhibition in established organoids. 
In the second part of this thesis, we evaluated a targeted therapy using pan-
EGFR inhibitor, Afatinib, aimed at inhibiting Pancreatic CSC and hence abrogate tumor 
and metastasis. We begin by demonstrating the presence of higher CSC in patients 
treated with chemotherapy compared to patients with no history of chemotherapy 
highlighting the presence and role of CSC in PDAC. We then demonstrate the efficacy of 
treatment with Afatinib alone and in combination with gemcitabine in organoids derived 
from human PDAC patients. We also show inhibition of primary tumor and metastatic 
incidence in an orthotopic mouse model of pancreatic cancer by combination therapy of 
Afatinib and gemcitabine. We also look at changes in the CSC population, KPC 
organoids and primary tumors in an orthotopic mouse model and find a significant 
decrease. Upon evaluation of effects of Afatinib on CSC population and KC, KPC 
organoids we reveal that Afatinib inhibits CSC stemness by downregulating CSC and 
self-renewal markers. Finally, we provide a mechanism of action for Afatinib and its 
validation by knockdown studies. Our findings indicate that Afatinib inhibits pancreatic 
CSC via EGFR/ ERK/ FOXA2/ SOX9 axis and a combination of Afatinib and gemcitabine 








TABLE OF CONTENTS 
LIST OF FIGURES ............................................................................................................. 7 
LIST OF ABBREVIATIONS ............................................................................................... 9 
ACKNOWLEDGMENTS................................................................................................... 13 
CHAPTER 1: REVIEW OF THE LITERATURE .............................................................. 15 
1.1 Introduction.............................................................................................................. 16 
1.2 Resectable Pancreatic Cancer ............................................................................... 17 
1.2.1 Adjuvant Therapy ............................................................................................. 17 
1.2.2 Neoadjuvant Therapy ....................................................................................... 22 
1.3 Nonresectable disease ........................................................................................... 24 
1.3.1 Locally advanced unresectable pancreatic cancer (LAPC) ............................. 24 
1.3.2 Advanced metastatic pancreatic cancer .......................................................... 26 
1.3.3 Second-line therapy.......................................................................................... 29 
1.4 Targeted therapies against PDAC .......................................................................... 31 
1.5 Targeting tumor microenvironment......................................................................... 32 
1.6 Immunotherapy ....................................................................................................... 35 
1.6.1 Checkpoint blockade ........................................................................................ 36 
1.6.2 Cancer vaccine ................................................................................................. 38 
1.7 Precision medicine .................................................................................................. 40 
1.8 Evaluating Therapy response with a grain of salt  .................................................. 43 
1.9 Conclusions ............................................................................................................. 44 
1.10. Figures and Legends ........................................................................................... 46 
CHAPTER 2: MATERIALS AND METHODS .................................................................. 53 
2.1 Cell culture .............................................................................................................. 54 
2.2 Isolation of CSC/side population............................................................................. 54 
2.3 Tumorsphere assay and drug treatments .............................................................. 54 
2.4 RNA isolation and quantitative real-time PCR (qRTPCR) ..................................... 55 
2.5 Transfection experiments........................................................................................ 55 
2.6 PC organoid development from LSL-KrasG12D/+; Pdx-1-Cre (KC), and LSL-
KrasG12D/+; LSL-Trp53R172H/+; Pdx-1-Cre (KPC) mouse tumors ..................................... 55 
2.7 In vivo xenograft mouse model and treatment strategy ......................................... 56 
5 
 
2.8 Immunoblot analysis ............................................................................................... 56 
2.9 Confocal immunofluorescence microscopy ............................................................ 57 
2.10 Immunohistochemistry .......................................................................................... 57 
2.11 Statistical analysis................................................................................................. 58 
CHAPTER 3: THREE-DIMENSIONAL ORGANOIDS AS PRECLINICAL MODELS .... 59 
3A. Review of Literature................................................................................................ 60 
3A.1 Introduction........................................................................................................ 60 
3A.2 Perquisites to Organoid Generation: Where do we start? ............................... 62 
3A.3 Source Tissue: Beginning decides the end ...................................................... 62 
3A.4 Importance of Matrix Selection ......................................................................... 63 
3A.5 Media requirements and properties of generated Organoids .......................... 64 
3A.6 Limitations: Need for Intervention ..................................................................... 74 
3A.7 Prospective application: Making the most of tremendous tool......................... 75 
3A.8 Conclusions and Perspectives: Towards modeling accurate homeostasis and 
disease....................................................................................................................... 77 
3A.9 Figures and legends.......................................................................................... 80 
3B Generation and optimization of organoid cultures  .................................................. 87 
3B.1 Background and rationale ................................................................................. 87 
3B.2. Results.............................................................................................................. 91 
3B.2.1 Generation of Organoids................................................................................ 91 
3B.2.2 Maintenance of progenitor cells or CSC pool in pancreatic cancer organoids.
 ................................................................................................................................... 95 
3B.2.3 Tracking Growth and therapy response in organoids ................................... 95 
3B.3 Discussion............................................................................................................. 97 
3B.4 Figures and Legends ............................................................................................ 98 
CHAPTER 4: PANCREATIC CANCER STEM CELL TARGETING: AFATINIB 
INHIBITS EGFR/FOXA2/SOX9 AND DECREASE STEMNESS PROPERTY ............. 106 
4.1 Introduction............................................................................................................ 107 
4.2 Results................................................................................................................... 109 
4.2.1 High self-renewal marker expression in Gemcitabine treated and high-grade 
pancreatic cancer. ................................................................................................... 109 
4.2.2. Development and characterization of murine PC organoids  ........................ 110 
6 
 
4.2.3. Combination of afatinib and gemcitabine significantly inhibits PC cell growth 
and in vivo primary tumor and metastasis............................................................... 112 
4.2.4. Afatinib decreases the SP/CSC population and tumorsphere formation in PC 
cells. ......................................................................................................................... 113 
4.2.5. Treatment of afatinib significantly decreases the CSC markers in tumor 
organoids and in pancreatic xenograft tumors ........................................................ 114 
4.2.6. Afatinib abrogates CSC markers and oncogenic signaling in CSCs............ 115 
4.2.7. Afatinib decreases CSC populations via ERK/FOXA2/SOX9 signaling in 
PCSCs. .................................................................................................................... 116 
4.3 Discussion ............................................................................................................. 118 
4.4. Figures and Legends ........................................................................................... 122 
CHAPTER 5: SUMMARY, CONCLUSIONS AND FUTURE DIRECTIONS ................. 148 
5.1 Summary ............................................................................................................... 149 
5.1.1 Organoids for preclinical research ................................................................. 149 
5.1.2 Afatinib targets CSCs in PDAC ...................................................................... 150 
5.2 Conclusions ........................................................................................................... 153 
5.3. Future Directions .................................................................................................. 154 
5.3.1 Organoids for preclinical research ................................................................. 154 
5.3.2. Afatinib targets CSCs in PDAC ..................................................................... 156 
CHAPTER 6: REFERENCES......................................................................................... 159 
REFERENCES................................................................................................................ 160 







LIST OF FIGURES 
CHAPTER 1 
Fig. 1.1  Treatment guidelines for potentially curable pancreatic cancer. 
  
Fig. 1.2  Treatment guidelines for borderline resectable or locally advanced 
pancreatic cancer. 




Fig. 3.1  Representation of the organoids generated and the media compositions 
required 
Fig. 3.2  General scheme of generating organoids and representative figures of 
organoids generated by our laboratory 
Fig.3.3   Potential applications of organoids generated 
Fig.3.4  Established KC, KPC ad Human PDAC organoids 
Fig.3.5  CSC population is maintained in pancreatic cancer organoids 
Fig.3.6  Organoids growth in culture 




Fig.4.1  High self-renewal marker expression in Gemcitabine treated and high-
grade pancreatic cancer 
8 
 
Fig.4.2  Effects of afatinib on the development of pancreatic cancer (PC) 
organoids 
Fig. 4.3  Afatinib and gemcitabine combination treatment inhibits pancreatic tumor 
growth and metastasis in an in vivo xenograft mouse model 
Fig.4.4  Afatinib inhibits cancer stem cell (CSC) counts and stemness 
Fig.4.5  Afatinib and gemcitabine combination inhibits pancreatic CSCs (PCSCs) 
in KPC mouse tumor organoids and primary mouse tumors 
Fig.4.6  Afatinib inhibits CSC stemness by downregulating multiple CSC markers 
in PC cells. 
Fig.4.7 Afatinib decreases the CSC population via EGFR/ERK/FOXA2/SOX9 
signaling in PCSCs.  
Supplementary Figure 1 
Supplementary Figure 2 
Supplementary Figure 3 
Supplementary Figure 4 




LIST OF ABBREVIATIONS 
ADCC   Antibody-dependent cellular cytotoxicity 
AFE   Anterior foregut endoderm 
ALCAM  Activated leukocyte cell adhesion molecule 
APACT Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as 
Adjuvant Therapy for Patients with Resected Pancreatic Cancer 
AR   Androgen receptor 
ATCC   American Type Culture Collection 
ATP   Adenosine triphosphate  
ATRA   All Trans Retinoic Acid 
BRAF   Serine/threonine-protein kinase B-raf coding gene 
CAF   Cancer-associated fibroblasts 
CRP   C-reactive protein 
CSC   Cancer stem cell  
CST   Cell Signaling Technology 
DE   Definitive endoderm 
DHT   Dihydrotestosteron 
DMEM   Dulbecco’s minimal essential Medium 
DMSO   Dimethyl sulfoxide 
ECM   Extra Cellular Matrix 
ECOG   Eastern Cooperative Oncology Group 
EGF   Epidermal growth factor 
EGFR   Epidermal growth factor receptor 
ESA   Epithelium Specific Antigen 
ESC   Embryonic stem cells 
10 
 
FA   Folinic acid 
FACS   Fluorescence-activated cell sorting 
FBS   Fetal bovine Serum 
FDA   Food and Drug Administration 
FGF   Fibroblast growth factor 
FOLFOX  Folinic acid (leucovorin) fluorouracil (5FU) 
GVAX GM-CSF (granulocyte-macrophage colony-stimulating factor) 
secreting vaccine 
H&E   Hematoxyline and Eosin 
HEPES  4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HGF   Hepatocyte Growth Factor 
HIFU   High- intensity focused ultrasound 
HLO   Human lung organoids 
IMPaCT  Individualized Molecular Pancreatic Cancer Therapy 
IRE   Irreversible electroporation 
LAK   Lymphokine-activated killer 
LAPC   Locally advanced unresectable pancreatic cancer 
MDSC   Myeloid-derived suppressor cell 
MEC   Mammary epithelial cell 
MMTV   Mouse mammary tumor virus 
MTT   3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
NEOPAC  Neoadjuvant Paclitaxel 
NSCLC  Non-small cell lung carcinoma 
OOPD   Office of Orphan Products Development 
PBS   Phosphate buffer saline 
PC   Pancreatic cancer 
11 
 
PCNA   Proliferating cell nuclear antigen 
PCR   Polymerase chain reaction 
PDAC   Pancreatic ductal adenocarcinoma 
PSC   Pancreatic stellate cells 
PCSCs  Pancreatic cancer stem cells 
QOL   Quality of life 
QPCR   Quantitative PCR 
QRTPCR  Quantitative real time PCR 
RA   Retinoic Acid 
RECIST  Response evaluation criteria in solid tumors 
RIPA   Radio-immunoprecipitation assay buffer 
RNA   Ribonucleic Acid  
RSPO   R-Spondin1 
RTPCR  Real Time PCR 
SC   Stem Cells 
SFRO   Sociéte Française de Radiothérapie Oncologique 
SHH   Sonic hedgehog 
SMA   Smooth muscle actin 
SMO   Smoothened homolog precursor 
SP   Side population 
SPARC  Secreted protein acidic and rich in cysteine 
TIL   Tumor-infiltrating lymphocytes 
USFDA  United States Food and Drug Administration 
VAFE   Ventral anterior foregut endoderm 
VEGF   Vascular endothelial growth factor 
WAP   Whey acidic protein 
12 
 
























I want to express profound gratitude to my advisor, Dr. Surider K Batra, for his 
continuous support, encouragement, and guidance through my graduate training. His 
valuable support and encouragement enabled me to complete my work successfully. Am 
indebted to him for imbuing and teaching me valuable lessons in critical thinking and 
innovative thought process. His positivity, enthusiasm and his giving nature are awe-
inspiring. I would also like to thank Dr. Moorthy Ponnusamy for his supervision and 
support. He has been a constant source of guidance. I would also like to thank my 
supervisory committee members Dr. Apar Ganti, Dr. Joyce Solhiem, Dr. Michael. 
Hollingsworth, Dr. Ram Mahato, Dr. Moorthy P. Pannusamy and Dr. Amar Singh for their 
support, guidance, and encouragement.  
 I want to thank the past and the present members of the Batra lab including Dr. 
Parthasarathy Sheshacharyulu, Dr. Satyanarayana Rachagani, Dr. Surshil Kumar, Dr. 
Raghupathi Vengoji, Dr. Imayvaramban Lakshmannan, Sanchita Rauth, Ramakrishna 
Nimmakayala and Kavita Mallya. Thank you for the useful discussions and for sharing 
your experience with me.  
 I would also like to thank the University of Nebraska Medical Center, especially 
the Department of Biochemistry and Molecular Biology for the support and providing an 
encouraging environment to pursue my graduate studies. I am also very thankful to the 
graduate school for UNMC graduate studies assistantship and financial support. 
 Finally, I would like to thank my family and friends for their love, support, and 
encouragement. I would especially like to thank my parents and my husband for 
believing in me and helping me. I am also thankful to my parents-in-law for their 
blessings. I am also grateful to my brothers and sisters for their prayers and 
14 
 
encouragement. I would forever be indebted to my family and my mentors for 
















































Pancreatic cancer (PC) accounts for 3% of cancer instances in the United States (US) 
but claims 7% of all cancer-related deaths. The past 30 years of constant efforts have 
managed to increase the five-year median survival rates from 3% to 9% [4]. Such dismal 
patient survival warrants better therapeutic interventions. Pancreatic ductal 
adenocarcinoma (PDAC) is the most common form/manifestation of PC. Late diagnosis 
of PDAC, due to the internal location of the organ and lack of distinct symptoms, leaves 
PC patients with very few therapeutic options. Additionally, PC poses major recalcitrance 
to therapy due to extensive stroma which prevents drugs from accessing tumor cells and 
the presence of therapy-resistant cells or cancer stem cells (CSCs). Furthermore, PC is 
now being proposed as a systemic disease starting from its conception and hence early 
metastasis warrants development of systemic therapies [5]. 
Projections indicate that PC will be the second most common cause of death in 
the USA by 2030 with only non-small cell lung carcinoma (NSCLC) ahead of it [6]. PC 
patients when diagnosed have limited options for therapy. Over 50% of patients when 
diagnosed with PC, present a late stage disease with local and distant metastasis [4]. 
Most of these patients are not suitable for surgical resection, surgery being the only 
curative treatment available offers a survival of 15-20% [7]. However, most patients are 
not eligible for surgery. On diagnosis, cancer is staged from one to four on the basis of 
imaging and biopsies. Stage one and two are often surgically resectable but stage three 
is locally advanced and surgically unresectable and stage four is distant metastatic 
cancer. 
We saved around 11,000 lives in 2018 out of over 55,000 patients diagnosed 
with PC. This is where we stand on the road to therapy for PC. This figure although 
discouraging shows us how much more we can do. There is a lot unknown about the 
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disease. In this review, we discuss where we stand in the fight against PC, some 
available therapies and some options that may turn this fight in our favor. We also 
discuss some issues that need addressing for a better analysis of clinical trial results and 
future research avenues. 
1.2 Resectable Pancreatic Cancer 
1.2.1 Adjuvant Therapy 
Surgery is currently the only potentially curative procedure available for PDAC. However 
more than 90% of patients that undergo surgery show relapse and would die if not 
supplemented with additional therapy [7]. This is precisely the reason that adjuvant 
treatment has been the subject for several clinical trials in the last decade. The patients 
eligible for adjuvant therapy are advised chemotherapy, radiotherapy or a combination 
(Chemoradiotherapy; CRT) of both. Since the Gastrointestinal Tumor Study Group 
(GITSG) trial in 1985 many trials have compared different adjuvant therapy regimens 
and if there is a need for adjuvant therapy [8]. GITSG was a randomized phase 3 trial 
that enrolled 43 patients and compared the adjuvant therapy of 5 fluorouracil (5FU) 
chemo with radiotherapy followed by two years of 5FU alone to observation only. The 
trial was terminated due to poor accrual of patients and increasingly large survival 
difference between study arms, but a significant difference in average survival of control 
arm vs. treatment arm (11 months vs. 20 months) could be observed. Although the study 
only recruited patients with negative resection margins thereby selecting people already 
prognostically favored, its results did impress upon the survival benefit of adjuvant 
therapy over no therapy after surgical resection of the tumor. Many studies after that 
have looked at the benefit of therapy after surgical intervention. Two options often 
recommended to patients are CRT and chemotherapy alone. An European organization 
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for research and treatment of cancer (EORTC) multicenter phase 3 randomized trial 
enrolled 218 patients and compared the benefits of adjuvant CRT versus observation 
only and found that CRT offers a survival advantage which was not statistically 
significant (overall survival of 17.1 months in treatment vs. 12.6 months in observation-
only arm); [9]. Another study by European Study Group for Pancreatic Cancer (ESPAC), 
published a multicentral randomized trial (ESPAC1) in 2004 which recruited 289 patients 
and tried to weigh chemotherapy, CRT and observation only against each other [10]. 
They compared the 5-year survival rates and found that 5FU-based-CRT offers a 
survival disadvantage over observation alone (10% versus 20% 5-year survival rates 
P=0.05). But 5-FU-chemotherapy after R0 or R1 resection showed a survival advantage 
by increasing 5-year survival to 21% when compared to no chemotherapy which was 8% 
(P=0.009). This survival benefit was very encouraging since 18 percent of the patients 
had positive resection margins, which was an exclusion criterion in the GITSG clinical 
trial [8],[10]. The CRT and hence its negative results in ESPAC1 trial were criticized by 
the radio-oncologists; on the contrary, similar survival results for CRT were observed in 
RTOG97-04 trial [11]. RTOG97-04 trial compared CRT with 5FU to CRT with 5FU 
followed by Gemcitabine and found no survival benefits.  
Although ESPAC1 study proved the benefit of 5-FU chemotherapy as adjuvant 
therapy, out of 289 patients enrolled 237 died by the end of the study. This still means 
only 12% of enrolled patients survived. Cumulative results of this study put a serious 
question on the use of CRT as adjuvant therapy, by highlighting the detrimental effects 
of chemoradiation. Radiation therapy administration delays chemo administration and 
may also generate a more resistant tumor population if we consider the recent studies 
published, which claim radiation therapy enriches the cancers stem cell population [12, 
13]. These may be the reason behind the overall decrease in 5-year survival with CRT. 
A small sample size of GITSG study along with results published from EORTC study and 
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ESPAC1 trial overwhelmed the GITSG study results and favored chemotherapy as the 
more effective adjuvant therapy. A meta-analysis of randomized adjuvant therapy trials 
done by Stocken et al. in 2005 compared five trials including ESPAC and concluded that 
adjuvant therapy reduces the risk of death by 25% which was statistically significant[14]. 
There was a median survival of 19 months with chemotherapy and 13.5 months without 
it. Whereas, chemoradiation showed no significant difference in the risk of death with 
median survivals of 15.8 months with chemoradiation and 15.2 months without. 
Subgroup analysis revealed chemoradiation was more effective (p=0.04) when 
compared to chemotherapy (p=0.007) in patients with a positive resection margin [14]. 
Over time, multiple studies have compared various adjuvant chemotherapy regimens out 
of which some notable drugs are gemcitabine and 5FU, a combination of both and 
FOLFIRINOX (folinic acid, fluorouracil, irinotecan hydrochloride and oxaliplatin). Since its 
arrival in the scenario of PC therapy in 1996, gemcitabine has taken center stage as a 
standard of care for treatment of this disease. CONKO-001, a multicentral phase 3 
randomized clinical trial compared median disease-free survival, 5-year overall survival 
and 10-year survival of 368 patients divided into two groups of gemcitabine adjuvant 
therapy and observation alone [15]. The results depicted that gemcitabine adjuvant 
therapy led to a median disease-free survival of 13.4 months compared to 6.7 months 
with observation only. Gemcitabine group also had increased overall 5-year (20.7%) and 
10-year (12.2%) survivals compared to control groups of observation only 5-year 
(10.4%) and 10-year (7.7%) survival rates [15, 16]. Enduringly, ESPAC 3 compared 5FU 
with folinic acid versus gemcitabine and found no statistical difference in the survival 
advantage offered by the two drug regimens [17]. The median survival of 5FU + folinic 
acid was 23.0 months compared 23.6 months with gemcitabine. Median progression-
free survival was also 14.1 and 14.3 months respectively. Although gemcitabine alone 
did not have a significant survival advantage over 5FU+folinic acid, its toxicity profile was 
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significantly better than later. A retrospective analysis of ESPAC 3 trial suggested a role 
of ENT1 (equilibrative nucleoside transporter 1, a key mediator for gemcitabine cellular 
uptake) in stratifying patients for adjuvant administration of gemcitabine [17, 18]. Another 
prospective study analyzed the prognostic influence of gemcitabine-related genes 
(hENT1, ribonucleotide reductase subunits (RRM1, RRM2), and deoxycytidine kinase 
(dCK) ) in 100 patients undergone gemcitabine adjuvant therapy and identified low 
expression of hENT1 and dCK, and high/moderate levels of RRM1 as negative 
prognostic factors [19]. These studies suggest stratification of patients before adjuvant 
therapy administration although further prospective validation is required. Other 
components of major drug metabolic pathways could be used to refine therapeutic 
approaches further and generate more personalized treatment regimens. Patient 
prognosis was also influenced by the ability of the patient to complete all six cycles of 
chemotherapy [20]. Considering CONKO-001 trial results that established a 6-month 
course of adjuvant chemotherapy (gemcitabine) as the standard of care for resected PC 
patients and the positive results of the PA.3 phase III trial [21] demonstrating a survival 
benefit from the addition of erlotinib to gemcitabine (although in metastatic disease) 
CONKO-005 trial was designed [22]. The trial revealed no difference in median disease-
free survival or median overall survival of gemcitabine and erlotinib combination over 
gemcitabine alone. Although a trend toward better long-term survival in favor of 
gemcitabine and erlotinib group was observed (estimated survival after 1, 2, and five 
years for combination group was 77%, 53%, and 25% v 79%, 54%, and 20% for 
gemcitabine alone group, respectively). A randomized phase III clinical trial conducted 
on Japanese population revealed adjuvant therapy of S-1 (combination of tegafur-
chemotherapeutic prodrug of 5FU, and chemotherapeutic adjuncts gimeracil (Stabilises 
5FU) and oteracil potassium(reduces 5FU activity)) provided a 5-year survival of 44.1% 
compared to gemcitabine which allowed a 5-year survival of 24.4% [23]. Hence, the 
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study proposed S-1 as a standard of care for PDAC although the results of this study 
have not been confirmed in non-Asian populations. A recent trial ESPAC-4 compared 
gemcitabine monotherapy with gemcitabine plus capecitabine combination therapy in 
patients with R0 (42% patients) or R1 (60% patients) resected PC. Median overall 
survival was 28 months for patients in the gemcitabine plus capecitabine group 
compared with 25·5 months in the gemcitabine group [24, 25]. Consequently, in 2017 
the American Society of Clinical Oncology (ASCO) clinical practice guidelines were 
updated for potentially curable PC. Updated guidelines direct patients with resected PC 
and no prior preoperative therapy to be offered 6 months of adjuvant chemotherapy in 
the absence of medical contraindications. In patients with no concerns for toxicity or 
tolerance, the doublet regimen of gemcitabine and capecitabine should be preferred. 
Alternatively, monotherapy with gemcitabine or 5-FU plus FA can be offered as an 
adjuvant treatment initiated within 8 weeks of surgical resection, assuming complete 
recovery [26]. Another important clinical trial named APACT compares doublet therapy 
of nab-paclitaxel plus gemcitabine with gemcitabine monotherapy, and its results are still 
pending [27]. In 2018 results of PRODIGE 24/CCTG PA.6 trial were released which 
showed a large increment in treatment benefit over gemcitabine [28]. PRODIGE 24 was 
a randomized phase III trial including 493 patients with surgically removed PC. The trial 
compared mFOLFIRINOX (modified FOLFIRINOX containing oxaliplatin, leucovorin, 
irinotecan, and fluorouracil) with gemcitabine adjuvant therapies given 3 to 12 weeks 
after surgery for 6 months. The median disease-free survival and median overall survival 
observed in the mFOLFIRINOX group (21.6 and 54.4 months) was higher than in the 
gemcitabine group (12.8 and 35.0 months). At a median follow up patients in 
mFOLFIRINOX lived a median of 20 months longer. Patients in the mFOLFIRINOX 
group also exhibited delayed metastasis (median = 30.4 months vs. 17.0 months with 
gemcitabine) and were cancer-free 9 months longer than those who received 
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gemcitabine. Overall, mFOLFIRINOX led to more severe symptoms for patients but were 
mostly manageable as the authors of the study report[28]. The symptoms described for 
mFOLFIRINOX included diarrhea, nausea, vomiting, and fatigue. The side effects 
mentioned for gemcitabine included swelling, headache, flu-like symptoms, and low 
white blood cell counts. Both treatments were reported to cause low levels of white blood 
cells and fever [28]. 
1.2.2 Neoadjuvant Therapy 
Immediate surgery followed by chemotherapy is the current standard of care for PC 
patients with a resectable disease, but an emerging strategy for resectable, borderline 
resectable or locally advanced unresectable cancer is neoadjuvant therapy [25]. In this 
scheme of treatment patients are given radiotherapy, chemotherapy or 
chemoradiotherapy followed by surgically removing the tumor, also called preoperative 
therapy [25, 29]. The first randomized clinical trial results for neoadjuvant therapy came 
in 2015 [25]. Which compared neoadjuvant chemoradiation with gemcitabine/cisplatin 
and surgery to surgery alone [30]. The trials concluded that the preoperative treatment 
was safe concerning toxicity and mortality, but the results were not statistically 
significant. The trial had to be terminated due to slow accrual before it could be 
completed. Apart from this study, there had been several meta-analyses and few 
prospective and nonrandomized trials evaluating the benefits of neoadjuvant 
chemoradiotherapy (mostly gemcitabine-based) but no notable randomized trials [31]. 
The first randomized, phase III trial (PREOPANC-1) that found that patients who 
received chemoradiotherapy before pancreatic cancer surgery (preoperative) had better 
disease-free survival than those who started their treatment with surgical tumor 
resection, which is the current standard of care, were released in 2018 [29]. The trial 
enrolled 246 patients eligible for surgical resectable pancreatic cancer who were 
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randomly assigned to two groups. The first group received immediate surgery and the 
second group received chemoradiotherapy for ten weeks followed by surgery. Both the 
treatment regimens were followed by chemotherapy after surgery, with the total amount 
of chemotherapy given being equal in both groups. Chemotherapy was delivered in two 
parts in the chemoradiotherapy group which received part of the before surgery and the 
rest after [29]. The median overall survival and time until pancreatic cancer recurrence 
was higher for patients receiving preoperative chemoradiotherapy (17.1 and 9.9months) 
when compared with the ones who underwent immediate surgery (13.7 and 7.9 months). 
Two years survival rate was also higher with preoperative treatment than with immediate 
surgery (42% vs. 30%). 72% of patients underwent resection in the immediate-surgery 
group and 62% in the chemoradiotherapy group [29]. A higher proportion of preoperative 
treatment group patients saw successful microscopic surgical resection when compared 
to the immediate surgery group (63% vs. 31%). Among patients with R0 margins, the 
difference in median survival was greater, 42.1 months with preoperative treatment 
versus 16.8 months with immediate surgery. FOLFIRINOX chemotherapy or 
FOLFIRINOX combined with stereotactic body radiation therapy appear promising from 
other studies and should be tested against preoperative gemcitabine and radiation in a 
randomized clinical trial [32].  
Another multicenter, randomized controlled phase III trial called NorPACT- 1 
investigates benefits of neoadjuvant chemotherapy based on FOLFIRINOX over surgery 
with both groups receiving adjuvant chemotherapy with gemcitabine and capecitabine in 
90 patients [33]. The trial was organized by the Norwegian 
Gastrointestinal Cancer Group for Hepato-Pancreato-Biliary cancer for resectable 
cancer of the pancreatic head to decrease early mortality (within one year) in resected 
patients. Another notable multicenter randomized phase III trial designed to explore the 
efficacy of neoadjuvant chemotherapy is NEOPAC trial [33]. In patients with resectable 
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pancreatic adenocarcinoma in the head of the pancreas were randomized to surgery 
followed by adjuvant gemcitabine for six months or neoadjuvant gemcitabine and 
oxaliplatin followed by surgery and the same adjuvant treatment. Neoadjuvant 
chemotherapy would be given four times every two weeks [33]. 
Neoadjuvant chemoradiation is also being evaluated for providing substantial local 
control of borderline resectable pancreatic cancer and prolong patient survival. An open-
label, multicentre, prospective phase II trial that was designed to assess S-1 
chemotherapy with radiotherapy as neoadjuvant treatment [34]. Participants would 
receive S-1 and concurrent radiotherapy, with surgery after 3-8 weeks which will last 36-
month period with a minimum 24-month follow-up [34]. 
1.3 Nonresectable disease 
1.3.1 Locally advanced unresectable pancreatic cancer (LAPC) 
More than half of the patients that present with pancreatic cancer are diagnosed at the 
LAPC stage and have a discouraging survival rate of less than 5% [25]. These groups of 
patients depict local invasion of adjacent structures, generally vascular and are 
challenging to treat. Unlike resectable PC, LAPC patients rarely undergo resection with a 
curative intent instead of local control, symptom management and quality of life are the 
primary goals of the therapy [25].  
Initial systemic (induction) chemotherapy with combination regimens is usually 
recommended for most patients who can tolerate aggressive therapy. There is 
conflicting evidence for chemoradiotherapy versus gemcitabine chemotherapy alone 
[25]. ECOG (Eastern Cooperative Oncology Group) 42201 trial results in favor 
chemoradiotherapy whereas 2000‑ 01 Fédération Francophone de Cancérologie 
Digestive (FFCD)/Sociéte Française de Radiothérapie Oncologique (SFRO) trial favors 
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gemcitabine chemotherapy alone [35, 36]. No standard therapy is proven to be clinically 
superior to others, and hence an informed decision has to be made by the physicians 
considering risks and benefits for the patients. Therapies recommended for metastatic 
patients are often referred to due to lack of evidence for LAPC. 
Since 1997 till 2011 gemcitabine was considered standard of care for patients with 
unresectable pancreatic cancer. A definitive clinical trial assessing Gemcitabine versus 5 
FU as first-line treatments for patients with locally advanced pancreatic cancer was 
conducted [37]. Results from this trial established that gemcitabine improves disease-
related symptoms and survival in patients with pancreas cancer (5.6 vs. 4.4 months) 
[37]. Although the overall survival increment was small, the 12 months survival rate was 
improved significantly (18% for gemcitabine vs. 2% for 5-FU patients). Many trails since 
have worked on improving the overall survival and quality of life for patients with 
advanced pancreatic cancer by adding one or more drugs to gemcitabine and exploring 
different schedules (fix dose rate) of its administration. None of the trials resulted in 
clinically appreciable improvement in patient survival over gemcitabine till 2011, 
PRODIGE4/ACCORD11 trial which revealed FOLFIRINOX, a combination of 4 drugs 
(irinotecan, oxaliplatin, folinic acid, and 5-fluorouracil) showed a moderate improvement 
in overall survival of patients [28]. Local therapies for the management of tumors are 
recommended if the patients do not show a metastatic disease after induction 
chemotherapy. Several Local, regional therapies have been tested for LAPC 
management including irreversible electroporation (IRE), radiofrequency ablation (RFA), 
stereotactic body radiation (SBRT), high- intensity focused ultrasound (HIFU) [38]. RFA 
and SBRT are the best-studied modalities, and SBRT is the only treatment that has 
resulted in the quality of life improvements in patients with LAPC. SBRT has been 
studied with varying guiding techniques and radiation doses applied, and morbidity has 
been reported in up to 25% of patients [38]. SBRT minimizes the disruption in 
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chemotherapy since higher doses of radiation is given in shorter durations in contrast to 
radiotherapy. ASCO included SBRT in their recommendations for LAPC in 2016 [39]. 
Chemoradiotherapy or SBRT may be offered as an alternative to continuing 
chemotherapy alone for any patient with LAPC. CRT or SBRT may also be offered to 
patients who show local disease progression or toxicities after induction chemotherapy 
[38]. A short course of palliative radiotherapy (5 to 10 treatments) may be offered to 
patients with LAPC who have severe GI symptoms. Prolonged survival, better 
symptomatic management, and tumor regression as a result of local ablative therapies, 
has been reported in several studies [38]. However, utilization of local treatments should 
undergo further evaluation since approximately 30% to 50% of patients presenting with 
LAPC have evidence of metastatic disease within three months. Owing to the lack of 
RCTs conclusive data supporting local ablative therapies for LAPC is sparse [38].  
1.3.2 Advanced metastatic pancreatic cancer 
Gemcitabine became the standard of care and choice for first-line therapy against 
advanced metastatic pancreatic cancer since the Burris et al. trial in 1997 [37]. Other 
Phase III trials since then evaluating single-agent gemcitabine monotherapy for 
advanced pancreatic cancer yielded a median survival of 5.0 to 7.2 months for patients 
[40]. In 2006, a Randomized phase III trial compared gemcitabine plus cisplatin with 
gemcitabine alone in patients with advanced PC. The trial included 195 patients and the 
doublet therapy arm showed a prolonged progression-free survival compared to 
gemcitabine monotherapy (5.3 months v 3.1 months). Median overall survival was also 
enhanced in patients treated with a combination of gemcitabine and cisplatin as 
compared with the Gemcitabine (7.5 v 6.0 months). However, it was not statistically 
significant. The results from this trial favored the combination of gemcitabine with 
cisplatin over gemcitabine monotherapy [40]. Another trial from the Swiss Group for 
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Clinical Cancer Research and the Central European Cooperative Oncology Group 
compared Gemcitabine plus capecitabine combination therapy with gemcitabine 
monotherapy in advanced pancreatic cancer in a randomized, multicenter, phase III trial 
[41]. Median overall survival was improved although not significantly with the addition of 
capecitabine by an average of 1.2 months (8.4 months in Gemcitabine and capecitabine 
arm vs. 7.2 months in Gemcitabine arm). Further analysis of the trial reviled that the 
combination therapy was significantly beneficial for patients with good performance 
score (KPS of 90 to 100) with median overall survival being 10.1 months for combination 
group versus 7.4 months for Gemcitabine group. Additionally, a meta-analysis of 
randomized clinical trials indicated a significant survival benefit to patients when 
Gemcitabine base therapies combined with either platinum analogs or fluoropyrimidines. 
Their subgroup analysis that included 38% of all patients included in the meta-analysis, 
Gemcitabine-based combination therapies were beneficial for patients with a good 
performance score but not for patients with a poor performance score [42]. Around the 
same time phase II studies showing survival advantage and benefits of single-agent 
Irinotecan, and oxaliplatin combination with fluorouracil came out [43, 44]. Considering 
synergistic observed between Oxaliplatin and irinotecan in vivo, an open-label phase I 
study assessed the triple combination of oxaliplatin plus irinotecan plus leucovorin/5-
fluorouracil in patients with advanced solid tumors and saw encouraging results. This 
prompted a phase II and later Phase III trial comparing a combination chemotherapy 
regimen of FOLFIRINOX (oxaliplatin, irinotecan, fluorouracil, and leucovorin) with 
gemcitabine as first-line therapy in patients with metastatic pancreatic cancer (PRODIGE 
4/ACCORD 11) [28]. The median overall survival and progression-free survival were 
both enhanced FOLFIRINOX group versus gemcitabine group(11.1 vs. 6.8 months and 
6.4 vs. 3.3 months, respectively) [28]. The trial reported FOLFIRINOX to be associated 
with a survival advantage but increased toxicity. Another phase III MPACT trial 
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compared nab-paclitaxel and gemcitabine combination therapy versus gemcitabine 
alone in patients with metastatic pancreatic cancer [28]. The study demonstrated a 
significant survival advantage of nab-paclitaxel and gemcitabine (8.5 vs. 6.7 months). 
Progression-free survival was also improved with the combination therapy over 
gemcitabine monotherapy (5.5 vs. 3.7 months). After the results of MPACT and 
PRODIGE trials, ASCO guidelines were updated to include the proposed therapies. 
Gemcitabine plus NAB-paclitaxel was recommended for patients with Eastern 
Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1, relatively 
favorable comorbidity profile, and tolerability for relatively aggressive medical therapy 
[28]. Whereas, FOLFIRINOX (leucovorin, fluorouracil, irinotecan, and oxaliplatin) was 
recommended for patients who have an ECOG PS 0 or 1, favorable comorbidity profile, 
and can tolerate aggressive medical therapy, with access to chemotherapy port and 
infusion pump management services. On the other hand, patients with metastatic 
pancreatic cancer ECOG performance status, two are referred gemcitabine 
monotherapy according to the ASCO Clinical Practice Guidelines updated in 2018 [45]. 
Another approach is to capitalize on the hypoxic environment in pancreatic 
cancer. TH-302 is a prodrug of cytotoxin Bromo-isophosphoramide mustard (Br-IPM) 
and is hypoxia-activated. Evofosamide was tested in a randomized phase II clinical trial 
in a combination of gemcitabine versus gemcitabine alone and resulted in a significant 
increment in Overall survival from 3.6 months (Gemcitabine alone) to 6 months [46]. 
Despite encouraging results from prior trials, evofosamide failed to significantly improve 
overall survival in combination with gemcitabine in previously untreated patients with 
unresectable locally advanced or metastatic PDAC in the randomized phase III 
MAESTRO trial [47]. The trial reported an increase in median progression-free survival 
in the combination group versus gemcitabine alone group (5.5 months versus 3.7 
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months) encouraging further thought into the therapy. The trial results were mostly 
disappointing except for Asian patients. Among 123 Asian patients, median OS of 12.0 
months could be achieved by the addition of evofosamide to gemcitabine versus 8.5 
months with placebo/gemcitabine [47]. This highlights how population diversity may 
affect results in a trial and the need for therapy regimens to be tested for diverse groups 
separately.  
1.3.3 Second-line therapy 
Most pancreatic cancers are refractory to front line therapies and hence have a dismal 
prognosis. The median overall survival remains less than 12 months despite the 
available front-line therapies warranting development of potent second-line therapies. 
Despite 16-18% of patients undergoing a second line therapy, there are very few phase 
III randomized clinical trials available for second-line treatment for metastatic pancreatic 
cancer. The first phase III study came from CONKO-1 study group comparing best 
supportive care with oxaliplatin, folinic acid (FA) and 5- fluorouracil (FU) and best 
supportive care in patients (BSC) not responding to gemcitabine therapy [48]. The trial 
had to be terminated after 46 patients due to insufficient patient accrual instead of 
planned 165 patients. Median second-line survival was 4.82 months for oxaliplatin, FA 
and FU (OFF) treatment and 2.30 months with best supportive care alone. Median 
overall survival for first-line therapy with gemcitabine followed by OFF was 9.09 and 
BSC was 7.90 months. Despite being terminated prematurely, this randomized trial 
provided the first evidence of second-line chemotherapy being superior to best 
supportive care alone for metastatic pancreatic cancer patients not responding to 
gemcitabine [48]. After the proven benefit of second-line therapy the follow up CONKO-
003 trial compare the second-line OFF treatment versus FF alone for gemcitabine-
refractory pancreatic cancer [49]. The study included 168 patients refractory to first-line 
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gemcitabine therapy who were randomly assigned to FF or OFF. The median overall 
survival and progression-free survival in the OFF group was 5.9 and 2.9 months, 
whereas the FF group was 3.3 and 2 months [49]. This significant improvement by 
addition of oxaliplatin in patient survival was without any clinically relevant enhanced 
toxicities [49].  
PDAC is characterized by an extensive desmoplastic reaction, which complicates 
drug delivery and access to the tumor. To circumvent the desmoplasia novel 
formulations and drug delivery mechanisms are being tested. This search was 
encouraged by improved survival data seen in the NAPOLI-1 study [50]. In NAPOLI-1 
trial a combination therapy of nanoliposomal irinotecan (MM-398) plus fluorouracil and 
folinic acid was tested in patients with advanced metastatic PC and a prior history of 
gemcitabine-based therapy, against monotherapy with nanoliposomal irinotecan or 
fluorouracil and folinic acid [50]. Although the median overall survival did not differ much 
between the monotherapies (nanoliposomal irinotecan4.9 months and fluorouracil and 
folinic acid 4.2 months), a combination of nanoliposome irinotecan with fluorouracil and 
folinic acid extended the overall survival to 6.1 months. The survival benefits were 
observed with a manageable safety profile. A follow-up report from the NAPOLI-1 study 
reported that overall survival benefits were maintained with no safety concerns. One-
year overall survival rates were estimated to be 26% with the combination therapy of 
MM-398 with fluorouracil and folinic acid and 16% with fluorouracil and folinic acid [50].  
There are very few studies testing second-line therapy after first-line therapy of 
FOLFIRINOX. Most available trials describe second-line therapy options after a first line 
treatment history of gemcitabine. A retrospective study of patients with advanced 
pancreatic cancer treated with FOLFIRINOX first-line therapy followed by either doublet 
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or single agent as second-line therapy reported better overall survival for single-agent 
chemotherapy [51]. On the contrary, an AGEO prospective multicenter cohort reported a 
median survival of 18 months from the start of first-line therapy of FOLFIRINOX and a 
second line therapy of nab-paclitaxel plus gemcitabine. Second-line therapy with nab-
paclitaxel plus gemcitabine could achieve an overall survival of 8.8 months and median 
progression-free survival of 5.1 months [52].  
Although new studies have reported a survival benefit from second-line therapy, 
in patients with good performance status further research is needed to device better 
second-line treatment. In 2018, ASCO updated recommendations for second-line 
treatment of advanced pancreatic cancer to include gemcitabine plus nanoparticle 
albumin-bound paclitaxel (nab-paclitaxel) as second-line therapy for patients with first-
line treatment with FOLFIRINOX and ECOG PS of 0 to 1 [45]. The recommendations 
further suggest options of Fluorouracil plus oxaliplatin, irinotecan, or nanoliposomal 
irinotecan as second-line therapy for patients with a history of first-line treatment with 
gemcitabine plus nab-paclitaxel, ECOG PS of 0 to 1, and access to chemotherapy port 
and infusion pump management services. Single-agent therapies of gemcitabine or 
fluorouracil are recommended for patients with ECOG PS of 2 and who can not tolerate 
more aggressive treatments [45]. 
1.4 Targeted therapies against PDAC 
Therapies targeting specific signaling pathways or molecules associated with cancer 
growth or survival are designed to target cancer cells, leaving healthy cells relatively 
unharmed. Several targeting agents have been evaluated over the years against PC 
alone and in combination with chemotherapeutic drugs. So far, none of the targeted 
therapies has yielded a significant benefit to patient survival except EGFR family-
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targeting erlotinib, which has produced a moderate survival benefit. In the past few 
years, many therapies targeting important signaling cascades in PC have failed in 
randomized clinical trials with gemcitabine-based chemotherapy [25].  
Targeted therapies have still to show a significant survival benefit for a collective 
patient population for pancreatic cancer, but patient stratification may improve therapy 
response. In a randomized phase III trial which compared gemcitabine plus erlotinib 
targeted therapy with gemcitabine [53] overall survival was significantly prolonged to 
6.24 months v 5.91 months for gemcitabine. Progression-free survival and one-year 
survival was also higher with erlotinib plus gemcitabine. Further analysis revealed that a 
subgroup of patients who developed skin rash upon erlotinib treatment had a median 
survival of 12 months [53]. A skin rash can be generally considered as a positive 
predictive marker for response to anti- EGFR therapy across tumor entities. However, 
the molecular mechanism behind this phenomenon is still unknown. Understandably, 
high molecular heterogeneity and extensive and complex stromal and inflammatory 
components may be the reason behind the failure of targeted therapies in an unselected 
population suffering from advanced PDAC, since molecular profile and stromal content 
affect the half-life, accessibility, and metabolism of the administered therapeutic agent.  
1.5 Targeting tumor microenvironment 
The pancreatic tumor microenvironment is characterized by immense stroma, hypoxia, 
and hypovascularization. The nature of the tumor microenvironment can be a guiding 
factor for appropriate therapy regimen. Antiangiogenic targeted therapies have not been 
beneficial, such as the vascular endothelial growth factor (VEGF) inhibitors, and 
multikinase inhibitors with antiangiogenic activity [25]. This may be attributed to the 
extensive stroma and hypovascular environment of pancreatic tumors. Exploiting the 
stroma to enhance chemotherapeutic drug delivery is an attractive prospect. After 
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patient survival was significantly improved with gemcitabine plus nab-paclitaxel over 
gemcitabine monotherapy Secreted protein acidic and rich in cysteine (SPARC) was 
proposed to enrich the concentration of nab-paclitaxel in the pancreatic cancer 
microenvironment [25]. SPARC is a cancer-associated fibroblast (CAFs) produced 
matricellular protein known to bind albumin and hence could enhance binding of nab-
paclitaxel to tumors and increase antitumor activity. However, no association to validate 
that theory could be observed [54]. 
The pancreatic cancer stroma contains several cell types, including inflammatory 
cells, blood vessels, nerve cells, and CAFs. Pancreatic stellate cells (PSCs) are 
activated fibroblasts and play a vital role in developing a pancreatic tumor[55]. Hence, 
PSCs are emerging therapeutic targets. Treatment with Vitamin D ligand calcipotriol 
could reverse activated PSCs to a quiescent state in a preclinical study. Since PSCs 
express high levels of vitamin D receptor, their inhibition led to decreased fibrosis and 
enhanced tumor uptake of gemcitabine [56]. A phase 1b study is currently underway 
testing a combination of two chemotherapy drugs gemcitabine and nab-paclitaxel with all 
trans retinoic acid (ATRA) in patients with locally advanced or metastatic pancreatic 
cancer [57]. Emerging preclinical studies have shown that a derivative of Vitamin A, 
ATRA, has the potential to remodel or suppress stroma to enhance antitumor efficacy of 
drugs [57]. 
  The stroma also comprises a variety of extracellular matrix, components, 
collagen, fibronectin, laminin, and hyaluronic acid. Hyaluronic acid readily binds fluid and 
increases intratumoral pressure to collapse vasculature and hence reduce drug uptake 
— Pegylated recombinant human hyaluronidase (PEGPH20) in an experimental drug 
that breaks up hyaluronic acid [58]. In a recent phase, II study the addition of PEGPH20 
to nab-paclitaxel/gemcitabine improved progression-free survival in patients with 
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metastatic pancreatic cancer with no prior treatment. Although the trial was briefly 
interrupted due to thromboembolic events in the PEGPH20 group, the risk of 
thromboembolic events was reduced in all patients with the use of enoxaparin 
prophylaxis although the median overall survival was not improved (9.6 vs. 9.2 months) 
amongst patients [58]. A retrospective analysis of the study revealed benefit to patients 
with hyaluronan-high tumors (overall survival of 11.5 vs. 8.5 months, Median 
progression-free survival of 9.2 months vs. 5.2 months) [58].  
However, extreme caution should be undertaken while targeting PDAC stroma. 
Results from mouse models and in-vitro studies are often not replicated in patient trials. 
In preclinical studies in mouse models inhibition of Hedgehog signaling with 
Smoothened homolog (SMO) inhibitor IPI-926 enhanced gemcitabine delivery to 
pancreatic tumors by inhibiting myofibroblast growth, collagen deposition, and Tumour 
vascularity [59]. However, the combination therapy of IPI-926 and gemcitabine failed 
improved survival over gemcitabine monotherapy and led to the termination of the trial 
due to the progression of disease in the treatment arm [59]. It was demonstrated later 
that longer-term IPI-926 administration did inhibit stroma and increase vascularization 
but enhanced tumor growth and metastasis in a preclinical mouse model of pancreatic 
cancer. Thus, the stroma seems to have dual roles of protecting against tumor 
progression and impairing drug delivery to the tumor [60]. Targeting it is a double edge 
sword, and more research is required to devise strategies to target the stroma and avoid 
compromising its protective role optimally. 
The hypoxic nature of the pancreatic tumor microenvironment offers a 
therapeutic window to target cancer cells selectively. Evofosamide failed to improve 
overall survival with statistical significance in an unselected population but was 
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significantly beneficial for Asian patients [47]. The study is another example of how 
patient stratification can alter clinical trial result interpretation. 
1.6 Immunotherapy 
Immune response plays dual-opposing roles in cancer biology. On the one hand, it 
regularly filters and eliminates cancerous cells, and on the other hand, it can potentiate 
tumor growth by suppressing host immune response. The immune suppressive 
microenvironment is one of the critical hallmarks of PC characterized by upregulation of 
immune suppressive module that helps tumor cells to evade and silence the host’s 
immune response [61]. Immune suppression is achieved either directly or indirectly by 
cancer cells. The mechanism used by cancer cells to bypass immune clearance includes 
directly expressing Teff cell inhibitory proteins on the cell surface and maintaining 
immunoinhibitory cytokine profile (CXCR2, IL8) via MDSCs and T cells indirectly [25]. 
A long-acting pegylated form of recombinant IL10, called pegilodecakin, 
stimulates the expansion of cytotoxic CD8 T cells and enhances their tumor infiltration 
[62]. The increased infiltration of CD8-positive T cells has been shown to improve patient 
prognosis. Hence exerts anticancer effects. Results from a previous phase I/Ib clinical 
trial demonstrated a good safety/tolerability profile and sustained antitumor effects for 
pegilodecakin in several cancers including pancreatic cancer [62]. A combination 
regimen of pegilodecakin and FOLFOX yielded a median progression-free and overall 
survival of 3.5 months and 10.2 months respectively [62]. The one-year survival rate for 
the combination regimen was 47% with a disease control rate of 79%, and a complete 
response rate of 11%. Following the encouraging results, a randomized clinical trial 
SEQUOIA is underway comparing a combination of pegilodecakin and FOLFOX to 
FOLFOX alone as second-line therapy in patients with pancreatic ductal 
adenocarcinoma after tumor progression during or following a gemcitabine-based 
36 
 
therapy [62]. Pegilodecakin was granted the designation of an Orphan Drug for the 
treatment of pancreatic cancer by the U.S. Food and Drug Administration (FDA) and 
European Commission. US FDA also granted Fast Track designation for pegilodecakin 
plus FOLFOX as a second-line therapy against PC. 
 Another new notable drug is immune modulating multicomponent complex, YS-
ON-001. It is an emerging immune-oncology product with a broad spectrum of immune 
modulating actions like activation of natural killer cells, regulation of macrophage 
polarization, induction of antitumor cytokines, and suppression of regulatory T 
cells. Animal studies with YS-ON-001 in multiple solid tumors, including, pancreatic 
cancers have demonstrated antitumor efficacy and good safety of the product. The FDA 
Office of Orphan Products Development (OOPD) has granted YS-ON-001 an Orphan 
Drug designation with the potential to provide safe and effective treatment, diagnosis, or 
prevention of rare diseases/disorders that affect fewer than 200,000 people in USA.  
1.6.1 Checkpoint blockade  
Checkpoint inhibitors or inhibitors targeting cell surface proteins that inhibit T effector 
cells have been subject of several studies trying to target PDAC, but none has yielded 
significant clinical benefit. Only phase I-II trials have published results with combination 
therapy including PD-1, PD-L1, and CTLA-4 inhibitors in PC patients and only reported 
only a small improvement over clinical trials of single-agent checkpoint blockade. α-
CTLA4 is a CD28 homolog and is expressed on T effector and regulatory cells and was 
the first checkpoint inhibitor to be targeted in phase II clinical trial with ipilimumab which 
did not yield an improvement in overall patient survival [63]. Ensuingly, several clinical 
trials utilized ipilimumab in combination with chemotherapy and immune stimulators  like 
GVAX [64]. Additionally, a phase one trial evaluated dose escalation of anti CTLA4 
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antibody with gemcitabine chemotherapy and reported safe and tolerable patient profile 
[65]. These studies encouraged further clinical trials testing alternative combinations and 
doses of anti CTLA4 therapy, most of which have not posted results yet.  
Several phase I-II trials have since demonstrated the feasibility and potential of 
improvement by adding checkpoint inhibitors to gemcitabine and/or nab-paclitaxel in the 
first- and second-line treatment settings in advanced pancreatic cancer [66-68]. 
Available evidence suggests that combination chemotherapy and checkpoint blockade 
may be more efficacious in a treatment-naïve setting compared to the second-line 
therapy for patients with advanced PDAC with increasing toxicity [66, 68]. Most notable 
results have been from a quadruplet regimen of gemcitabine plus  nab-paclitaxel plus 
durvalumab plus tremelimumab in treatment-naïve metastatic PDAC in a phase II trial 
[67]. Disease control rate was reported as 100% with 6-month survival rate as 80%, and 
the quadruple treatment was well tolerated. Pembrolizumab has also been tested in 
neoadjuvant setting with chemoradiation for borderline resectable PDAC in phase Ib/II 
trial [69]. A bifunctional anti-PD-L1 and TGFβ receptor II fusion protein have also shown 
tolerability in PDAC patients suggesting the possibility of multitargeted fusion constructs 
involving checkpoint blockade [70]. Selecting PDAC patients earlier in the treatment 
course will also allow patients to develop a full-scale immune response with less immune 
tolerance and more time to recover from immune-related adverse events.  
Several ongoing clinical trials are investigating combination therapies including 
checkpoint blockade in the perioperative setting to examine the efficacy of immuno-
oncology approach in the non-metastatic setting. Although CTLA4 and PD1/PDL1 are 
the most well-studied immune checkpoints, other immunoinhibitory molecules such as 
LAG-3, TIM-3, and A2AR, are also being considered for immunotherapy in clinical trials 
[71]. Immune cells express a CD40 at their cell surface, and its binding to the CD40 
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ligand expressed on CD4+ helper T cells results in the activation of APCs (Diehl L et al. 
1999). A phase I clinical trial evaluating CD40 agonist mAb therapy in combination with 
gemcitabine produced a tumor response in 19% of patients with unresectable 
chemotherapy naive pancreatic cancer [72]. Tumor biopsies from these patients showed 
limited tumor-infiltrating lymphocytes and abundant tumor-infiltrating macrophages. 
Currently, a phase I clinical trial is underway evaluating R07009789 (a CD40 agonist 
mAb) combination with gemcitabine and nab‐paclitaxel for patients with resectable 
pancreatic cancer. 
However, there are no large-scale randomized phase III trials comparing 
combination therapies with checkpoint inhibitors with the current standard of care in 
PDAC. Nevertheless, ongoing studies lay some path for future studies for combination 
regimens integrating checkpoint blockade. 
1.6.2 Cancer vaccine 
Cancer vaccines are aimed at enabling the host to generate a T cell-mediated immune 
response by augmenting antigen presentation. To elaborate onco-antigens are provided 
as vaccines, which when encountered by the host’s antigen presenting cells are 
degraded and displayed on their cell surface and presented to effector T cells and 
memory T cells. This primes the T cells to launch a cytotoxic T cell response and 
developing anti-tumor immunity [72]. Some relatively well-studied antigens common in 
PCs and potential targets for vaccine developments include MUC-1 (Mucin-1), MUC4 
(Mucin-4), mutated KRAS and CEA (Carcinoembryonic antigen) [73, 74].  
GVAX is whole cell vaccine composed of irradiated autologous pancreatic cancer cells 
genetically modified to secrete GM-CSF (granulocyte-macrophage colony stimulating 
factor). GM-CSF secreted by these PC cells potentially stimulates dendritic cells (DCs) 
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to prime both B- and T-cells against cancer cells. GM-CSF also enables enhanced 
antibody-dependent cellular cytotoxicity (ADCC) and potentiated LAK (lymphokine-
activated killer) cell toxicity through IL2 secretion. Ipilimumab combination with GM-CSF 
cell-based vaccine (GVAX) in a study of 30 patients resulted in enhanced median overall 
survival and one-year survival over ipilimumab alone (3.6 vs. 5.7 months and 7% vs. 
27%, respectively) [75]. It is notable that higher levels of mesothelin‐specific CD8+ T 
cells were observed in patients in both treatment arms indicating an improved anti‐
cancer T‐cell response and had prolonged overall survival. A potential caveat to 
checkpoint inhibitor therapy is lack of cytotoxic infiltrating cells and hence supplementing 
it with GVAX made sense. GVAX is currently being studied in patients with resectable 
pancreatic cancer in phase I/II clinical trial with or without PD-1 binding monoclonal 
antibody nivolumab (NCT02451982; clinicaltrials.gov). 
RAS mutations are the most common genetic mutations in pancreatic cancer. A vaccine 
called TG01 developed by Targovax contains seven mutated RAS peptides, which when 
injected into patients could potentiate programming of T cells to launch a cytotoxic 
immune response. A phase I/II clinical trial in Norway tested this peptide-based RAS 
mutation targeting cancer vaccine in pancreatic cancer patients undergoing 
chemotherapy. The trial included 32 patients and showed TG01 allowed an astounding 
survival advantage over 4.6 months, the median survival time after diagnosis for 
pancreatic cancer patients in Europe and allowed a median overall survival of just under 
three years. While these results are promising it will be interesting to explore the 
potential of TG01 when combined with checkpoint inhibitors. 
Immune modulation of tumor stroma 
CAFs are active members of PC and facilitate tumor suppressive environment. CXCL12 
is abundant in pancreatic cancer microenvironment, whereas CXCR4 is expressed on 
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cancer and endothelial cells. CXCL12 also acts as a chemoattractant for hematopoietic 
cells including macrophages and T cells since they express CXCR4.FAP+ stromal cells 
produce CXCL12( C‐X‐C motif chemokine ligand 12 ) which binds to CXCR4 ( C‐X‐C 
chemokine receptor type 4 ) and functions to promote cellular chemotaxis suggesting a 
mechanism of tumor‐stromal cross‐talk [76]. Although, depleting FAP+CAFs have shown 
synergy with a vaccine based or immune checkpoint-based immunotherapies in mouse 
models it is not advisable to, pan‐target FAP+ fibroblasts since they are vital for normal 
homeostasis and present unanimously in the human body [77, 78]. Mouse studies have 
shown treatment with AMD3100 (an antagonist anti‐CXCR4 mAb) lead to T‐cell 
mediated reduction in tumor growth [77]. AMD3100, commercially named Mozobil, is 
being evaluated in phase I clinical trial for its potential to enhance T‐cell infiltration in the 
tumor microenvironment of patients with advanced pancreatic cancer. 
1.7 Precision medicine  
Pancreatic cancer is a difficult disease to treat and diagnose principally due to late 
diagnosis and inter and intra-tumor heterogeneity. Early diagnosis of PC can enable 
better-informed decisions specific for stage and subtype of PC. The most reliable blood 
test for pancreatic cancer is a serum level of CA19-9 (carbohydrate antigen 19-9) higher 
than 37 U/ml. This test is 80.3% sensitive and 80.2% specific in detecting pancreatic 
cancer from healthy patients. CA19-9 level can also differentiate between benign and 
malignant pancreatic cancer by the specificity of 82.8% and a sensitivity of 78.2% 
[79]. However, the minimum requirement for sensitivity and specificity for an early 
detection test to improve patient survival and affordability if 88% and 85%. Efficient 
early detection of pancreatic cancer can enhance patient survival by 30-40% [6]. 
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 In an attempt to allow earlier and more accurate detection of PC a recent study 
proposed levels of glypican-1on exosomes isolated from patient plasma. The test set up 
a cut of at 7.6% glypican-1-positive exosomes and detection of benign or malignant 
pancreatic cancer from healthy patients reported in the study with astounding sensitivity 
and specificity of 100% [80]. Although cancer-specific exosome isolation avoids 
contamination by noncancer proteins, exosome isolation from patients is difficult in 
clinical practice. Genetic analysis of cell-free DNA from patient plasma is more feasible 
now due to the advent of next-generation sequencing on cell-free media. A recent 
study reported the diagnostic specificity of 100% and a sensitivity of 92.3% by 
analyzing 54 genes concomitantly in patient samples [81].If these studies are 
replicated in more extensive studies a more precise treatment regimen could be 
designed to allow better patient survival. 
 Owing to tumor heterogeneity and limited prevalence of distinct mutations in 
individual patients patient subgrouping is difficult. An amalgamation of high-
throughput genomic technologies and advanced system biology algorithms has the 
potential to utilize genomic features of pancreatic cancer and its microenvironment to 
facilitate the development of treatment protocols specific to patients. Last decade saw 
multiple studies subgrouping patient population resulting in two subtypes that had 
clinical prognostic relevance defined as classic and basal-like. The basal-like subtype 
of PC was associated with reduced median survival time, more activated stroma and 
increased expression of genes such as ITGAM, CCL13 and CCL18 on marcorphages, 
and members of the SPARC, WNT and MMP families [82]. The study utilized 
microarray data for subgrouping and suggested that an RNA-derived signature 
characterizes the Tumour better than the traditionally employed somatic mutations. 
 The first clinical trial evaluating personalized medicine over the standard of 
care gemcitabine in PC was IMPaCT (Individualized Molecular Pancreatic Cancer 
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Therapy) trial [83]. Patient subgroups that received targeted therapies based on tumor 
mutations were; mutated homologous recombination and DNA damage repair genes 
(BRCA1, BRCA2, PALB2 or ATM); amplified ERBB2; absence of KRAS mutations. None 
of the patients eligible for targeted therapy could be successfully treated in this study. 
UK Precision-Panc trial and the University of Toronto-initiated COMPASS trial 
(NCT02750657) are other similar studies utilizing sequencing data to define a patient 
population with deficient DNA repair mechanisms that could benefit from platinum-based 
chemotherapy. The feasibility of this method of detection is questionable due to the 
requirement of highly cellular tumors so the results would have to be critically 
analyzed. 
Despite the dearth of clinical trials supporting personalized therapy abundant 
treatment options are available in PC to define treatment strategies specific to tumors. 
Evidence suggests patients with high tumor expression of peroxisomal acyl-CoA oxidase 
one could benefit from tyrosine kinase inhibitor masitinib and gemcitabine [84]. Similarly, 
combination therapy with ruxolitinib (Janus kinase 1(JAK1)–JAK2 inhibitor) and 
capecitabine may favor patients with systemic inflammation depicted by elevated serum 
C-reactive protein (CRP) levels [85]. Another new promising study reported high tumor 
levels of hyaluronic acid to suggest a potential benefit from pegylated recombinant 
human hyaluronidase-based therapy [86] and lead to a biomarker-enriched phase III 
trial. Similarly, ENT1 and BRAF mutations (not KRAS mutations) expression was found 
to predict response with gemcitabine [18] and serine/threonine-protein kinase BRAF 
inhibitors respectively. A recent study evaluated 109 patient biopsies from PDAC 
patients and reported 22% of PC patients had high microsatellite instability (MSI-H). 
Considering prognostic relevance of MSI in colorectal cancer Americal Society of Cancer 
suggests Routine testing for dMMR or MSI-H to find patients for checkpoint inhibitor 
therapy or PD-1 immune checkpoint inhibitor pembrolizumab as second-line therapy.  
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The advent of organoids cultures has generated another fabulous platform for the 
development of personized therapy. Pancreatic tumor organoid cultures recapitulate 
the full spectrum of disease progression when transplanted orthotopically in 
syngeneic mice. Tumor organoids represent tumor heterogeneity and maintains 
cancer stem cells better than 2D culture and retain cell plasticities and epigenetic 
changes that reflect different stages of PDAC progression. Their utilization for drug 
screening is still in the nascent stage, and more studies are required to analyze if 
drug response is replicated in this model as other models of PC.  
Precision medicine approaches seem attractive and promising with the potential 
to facilitate the development of targeted therapies against specific mutation profiles of 
tumors taking into account the drug delivery, drug metabolism and adverse effects for a 
particular patient. The low tumor incidence and higher variations in targetable genes 
along with an implicit sampling bias due to tumor heterogeneity are possible limitations 
to the development of personalized medicine. 
1.8 Evaluating Therapy response with a grain of salt 
Most of our preclinical studies utilize traditional cell line cultures, which often lack 
the more common classical phenotype of PC. Although patient-derived xenograft studies 
can recapitulate PC subtypes, it is crucial to consider the inherent capacity of the tumor 
to engraft and grow when analyzing therapy response. 
Our current measure of clinical trial grades drug response by RECIST criteria which 
does not take the complete patient health into account and focuses on reduction in 
tumor size alone. This overshadows many positive or negative effects a drug could be 
making on patient health. FDA released guidelines suggest incorporation of patient-
reported outcomes or QOL(Quality of Life) assessments as primary, secondary, or 
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exploratory endpoints in clinical trials to develop therapeutic agents (USFDA 2009). A 
systematic review evaluated FDA approved cancer drugs and identified seven Trials that 
used validated health care related QOL assessment in inclusion criteria. Only one drug 
out of the seven retained FDA approval at the time of the study rest of the drugs 
produced either no effect, or worse, or mixed effects on QOL. European Medical Agency 
published similar guidelines encouraging QOL inclusion during the development of 
anticancer agents. Unfortunately, there are still limited studies using QOL endpoints in 
the registration of trials [87]. 
 Lack of patient accrual and a need for evidence-based therapies warrants 
evaluation in trial designs and evidence generation. Basket trials that test drugs in 
different cancers that share common alterations could overcome to the lack of accrual. 
Umbrella trials testing different drugs targeting different alterations in a single tumor type 
could help generate more reliable evidence and better assessment of the clinical 
studies. 
1.9 Conclusions 
Pancreatic cancer is a very deadly malignancy with many hurdles to the development of 
effective therapy. There have been improvements in the last decade in our ability to 
address PDAC primarily due to better perioperative care and more efficacious adjuvant 
and neoadjuvant treatments. The survival following tumor resection in early stage 
PDACs has almost doubled to reach 30%. Due to potent neoadjuvant therapies, patients 
eligible for surgical resection have increased by nearly 50%. Although improvement in 
metastatic disease is still small new combination regimens, have been beneficial to 
patients. The overall survival for PDAC is still dismal, and better therapeutic 
interventions are needed. Even though Immunotherapies have still to yield a 
breakthrough for PDAC and approaches targeting stroma are still engulfed in 
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complexities, we have made a lot of progress in our understanding of PDAC. The 
elaborate molecular makeup and unique stroma leading to tumor heterogeneity, disease 
recalcitrance to therapies are much more understood. Development of new experimental 
models like organoid culture and technological advances in landscaping the cancer 
genome, precision medicine seems closer than ever. We need better analysis of results 
from our studies and reevaluate our study designs to incorporate the new information 
generated in recent years and including QOL as an endpoint in our studies to make sure 




1.10. Figures and Legends 
Fig. 1.1 Treatment guidelines for potentially curable pancreatic cancer. 
 
Pancreatic cancer patients with borderline resectable or locally advanced disease are 
stratified according to performance status (defined by Eastern Cooperative Oncology 
Group score). The treatment chart represents a review of literature and guidelines from 
the American Society of Clinical Oncology.  
Surgical removal of the primary tumor and regional lymph nodes is usually 
recommended for patients with no evidence of metastasis who meet the comorbidity 
profile. Neoadjuvant therapy can also be suggested to these patients but is usually 
suggested when there are radiographic findings suspicion of metastasis, but no 
diagnostic evidence and comorbidity profile does not allow major surgery. 
Patients that undergo surgical resection with no preoperative therapy are suggested 6 
months of adjuvant treatment, which is initiated within 8 weeks of surgery, assuming 
complete recovery and absence of medical or surgical contraindications. A doublet 
treatment with capecitabine and gemcitabine is preferred in absence of toxicity 
concerns. Alternatively, patients can be offered monotherapy with gemcitabine or 
fluorouracil plus folinic acid. Adjuvant chemoradiation may be suggested to patients (no 
preoperative therapy) with microscopically positive margin (R1) and/or metastasis in 
lymph nodes after 4 to 6 months of systemic adjuvant chemotherapy. 
Patients who receive neoadjuvant treatment 6 months of total adjuvant therapy 














Fig. 1.2 Treatment guidelines for borderline resectable or locally advanced 
pancreatic cancer. 
Pancreatic cancer patients with borderline resectable or locally advanced disease are 
stratified according to performance status (defined by Eastern Cooperative Oncology 
Group score). The treatment chart represents a review of literature and guidelines from 
the American Society of Clinical Oncology.  
An induction chemotherapy (initial systemic therapy) is recommended for most patients 
with ECOG PS of 0 or 1 with favorable morbidity profile. Due to absence of randomized 
clinical trial data physicians may offer therapy on the basis of treatment of a metastatic 
PDAC. chemoradiotherapy or stereotactic body radiation therapy may be offered.  
chemoradiotherapy or stereotactic body radiation therapy may also be suggested to 
patients in case of local disease progression after induction therapy but lack of evidence 
for systemic spread and ECOG PS less than equal to 2. patients who have stable 
disease or responded to 6 months of induction chemotherapy but developed 
unacceptable chemotherapy-related toxicities can also be given chemoradiotherapy or 
stereotactic body radiation. 
Patients who do not benefit from first-line treatment should be offers treatment as per 



































Fig. 1.3 Treatment guidelines for metastatic pancreatic cancer. 
Pancreatic cancer patients with metastatic pancreatic are stratified according to 
performance status (defined by Eastern Cooperative Oncology Group score). The 
treatment chart represents a review of literature and guidelines from the American 
Society of Clinical Oncology. 
First-Line Treatment 
For patients with ECOG PS of 0 to 1 and favorable comorbidity profile FOLFIRINOX 
(leucovorin, fluorouracil, irinotecan, and oxaliplatin) is recommended when there is 
access to infusion pump. Gemcitabine plus NAB-paclitaxel is recommended for patients 
with an ECOG PS of 0 to 1 and a relatively favorable comorbidity profile. 
Whereas for patients who have an ECOG PS of 2 and/or a comorbidity profile that 
disqualifies more aggressive regimens monotherapy with gemcitabine is recommended 
which may be supplemented with either capecitabine or erlotinib as per the doctor’s 
decision. 
Patients with an ECOG PS ≥ 3 or with poorly controlled comorbidity profile should be 
offered cancer-directed therapy only on a case-by-case basis with emphasis on 
optimizing supportive care. 
Second-Line Treatment 
Routine testing for dMMR or MSI-H is recommended, for patients for checkpoint inhibitor 
therapy consideration. If tested positive a second line therapy with pembrolizumab may 
be suggested. 
FOLFIRINOX treated patients can be given Gemcitabine plus NAB-paclitaxel as second-
line therapy if patients maintain an ECOG PS of 0-1, a relatively favorable comorbidity 
profile and can sustain aggressive medical therapy. Fluorouracil plus nanoliposomal 
irinotecan, or irinotecan can also be suggested for such patients. 
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gemcitabine plus NAB-paclitaxel treated patients can be advised Fluorouracil plus 
oxaliplatin as second-line therapy if patients can support aggressive therapy and have 
an ECOG PS of 0 to 1, and relatively favorable comorbidity profile. 
A second-line therapy of Gemcitabine or fluorouracil can be considered if patients have 



















































2.1 Cell culture 
Capan1 and SW1990 cell lines were obtained from ATCC and were cultured in high 
glucose DMEM medium supplemented with 10% FBS and 1% penicillin-streptomycin. 
Cultures were routinely inspected for mycoplasma contamination and phenotypic 
variation. Cell lines were incubated in a humidified atmosphere at 37ᵒC with 5% CO2. 
Afatinib was purchased from Selleck Chemicals, TX, USA, while gemcitabine was 
obtained from Sigma Aldrich. Afatinib and gemcitabine were reconstituted in PBS as per 
manufacturer’s instructions. 
2.2 Isolation of CSC/side population 
The side population/CSC population was sorted using BD FACS Aria (BD Biosciences) 
after staining cells as shown previously [88]. One million cells in 1 mL of culture medium 
were stained with Hoechst 33342 (AnaSpec Inc., Fremont, CA, USA) (5 µg/ml) for one h 
at 370C. Verapamil (Sigma) control staining was performed at a final concentration of 50 
µM to set up side population gating. 
2.3 Tumorsphere assay and drug treatments 
An in vitro tumorsphere assay was performed using CSC and non-CSC populations 
isolated from SW1990 and Capan1 cells. The tumorsphere assay was performed as 
shown previously [89]. Briefly, cells were subjected to drug treatments and then seeded 
in low-attachment 24-well plates in DMEM/F12 (Invitrogen, Grand Island, NY, USA) 
medium supplemented with 1% B27 supplement, epidermal growth factor (EGF) (20 
ng/mL), and basic fibroblast growth factor (bFGF) (10 ng/mL). After seven days, spheres 
were viewed under the microscope, counted and photographed.  
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2.4 RNA isolation and quantitative real-time PCR (qRTPCR) 
For quantitative mRNA analysis, RNA was isolated using the QIAGEN RNeasy mini kit 
(Qiagen, Valencia, CA, U.S.A.), and its concentration was determined using a NanoDrop 
ND 1000 Spectrophotometer. cDNA was synthesized using oligo(dT)18 primer, and 
SuperScript II RNase reverse transcriptase (Invitrogen). qRTPCR was performed for 
genes that were screened by PCR array analysis. 
2.5 Transfection experiments 
SW1990-SP PC cells (0.5×106) were seeded in a 6-well plate and incubated for 24 h. 
After 24 h, cells were transiently transfected with two independent siRNA 
oligonucleotides specific for human EGFR (100 pmol) (Origene) and FOX2 (100 pmol) 
(Origene) using lipofectamine transfection reagent for 72 h. Non-targeting (siRNAs) 
oligonucleotides were used as transfection control. After 72 h of incubation, cell lysates 
were isolated using RIPA buffer and subjected to western blotting and protein 
expression analysis. 
2.6 PC organoid development from LSL-Kras
G12D/+
; Pdx-1-Cre (KC), and LSL-
KrasG12D/+; LSL-Trp53R172H/+; Pdx-1-Cre (KPC) mouse tumors 
In brief, tumor organoids were established from KC and KPC autochthonous mouse 
models and subjected to enzymatic digestion with 0.012% (w/v) collagenase XI (Sigma) 
and 0.012% (w/v) dispase (GIBCO) in DMEM media containing 1% FBS (GIBCO); the 
extracts were embedded in growth factor-reduced Matrigel (BD Biosciences) [90]. 
Organoids were maintained and cultured in complete AdDMEM/F12 medium 
supplemented with HEPES (Invitrogen), Glutamax (Invitrogen), penicillin/streptomycin 
(Invitrogen), B27, Primocin (1 mg/ml, InvivoGen), N-acetyl-L-cysteine (1 mM, Sigma 
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Aldrich), mouse recombinant Wnt3a (100 ng/ml, EMD Millipore), human recombinant 
RSpondin1 (1 μg/ml, PeproTech), Noggin (0.1 mg/ml, PeproTech), epidermal growth 
factor (EGF, 50 ng/ml, PeproTech), gastrin (10 nM, Sigma), fibroblast growth factor 10 
(FGF10, 100 ng/ml, PeproTech), Nicotinamide (10 mM, Sigma), and A83-01 (0.5 mM, 
Tocris Biosciences).  
2.7 In vivo xenograft mouse model and treatment strategy 
Luciferase-labeled Capan1 cells (0.25x106 cells) were injected in vivo, orthotopically in 
the head of the pancreas in athymic nude mice. The successful injection was verified by 
the appearance of a fluid bubble without signs of intraperitoneal (IP) leakage. The 
abdominal wall was sutured, and the skin was closed with wound clips. Following tumor 
development in these mice (4 weeks after injection), we started therapy. Afatinib was 
administered orally (15 mg/kg/body weight) 45 times a week, and gemcitabine was given 
IP (50 mg/kg/body weight) twice a week. Following three weeks of treatments, mice 
were euthanized, and primary tumors and other organs were harvested for further 
analysis. 
2.8 Immunoblot analysis  
Western blot analysis was performed as described previously [91]. The blots were 
incubated with the following primary antibodies: pEGFR, EGFR, pHer2, Her2, pERK, 
ERK, FOXA2, SOX9, CD44V6, CD44, EpCAM, ALDH1, ABCG2, pFAK, FAK, NANOG. 
Secondary antibodies used were Rabbit, 1:1000; Cell Signaling Technology (CST)) and 
-Actin (mouse, 1:5000; Sigma Aldrich). 
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2.9 Confocal immunofluorescence microscopy  
Immunofluorescent labeling of cells was carried out by plating them at low density on 
sterilized coverslips. Cells were washed with 0.1mol/L HEPES containing Hank’s buffer 
solution followed by fixation with ice-cold methanol at -20°C for 2 minutes. Blocking was 
performed with 10% goat serum for at least an hour to avoid nonspecific staining. 
Primary antibody incubation was performed overnight at 4°C followed by PBS washes. 
The fluorescent conjugated secondary antibody was incubated for 1 hour at room 
temperature in the dark. The coverslips were inverted and mounted with Vectashield 
DAPI. Microscopic slides were prepared from formalin-fixed, paraffin-embedded samples 
of tumoroids (tumor organoids) and orthotopic tumors, de-paraffinized using xylene, and 
hydrated by a graded series of ethanol washes. Antigen retrieval was performed by 
microwave heating in 10 mmol/L sodium citrate buffer (pH 6.0) for 10 min. Sections were 
then probed with primary antibodies (1:200) diluted in PBS and incubated overnight at 
4°C. After washing twice with PBS, secondary antibodies (1:250) were added for one 
hour. Slides were again washed twice with PBS and images were taken under a 
confocal microscope.  
2.10 Immunohistochemistry 
Microscopic slides were prepared from formalin-fixed, paraffin-embedded samples of 
orthotopic tumors, de-paraffinized using xylene, and hydrated by a graded series of 
ethanol washes. Antigen retrieval was performed by microwave heating of slides in 10 
mmol/L sodium citrate buffer (pH 6.0) for 15 min. Endogenous peroxidase activity was 
quenched with 3% H2O2 in PBS for 30 minutes. After washing slides were subjected to 
30 minutes of blocking with Vectastain normal horse serum to block nonspecific binding. 
Sections were then probed with primary antibodies (1:200) diluted in PBS and incubated 
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overnight at 4°C. Sections were then washed and incubated with horseradish 
peroxidase-labeled secondary antibody for 30 minutes. Slides were washed and 
incubated with ABC solution (Vector Laboratories). The final reaction with 3,3’-
diaminobenzidine reagent (DAB) was carried as per manufacturers instructions to 
develop color. He slides were subsequently washed with water and counterstained with 
hematoxylin. This was followed by the dehydration process using increasing alcohol 
gradients and mounted with Vectamount permount mounting media(Vector 
Laboratories). 
2.11 Statistical analysis 
Statistical significance was assessed using two-tailed t-test and ANOVA tests using 
GRAPH PAD Prism software. All experiments were carried out in triplicates. For 
composite scoring of tissue array percentage of a cell stained (0-100%) were multiplied 
with the intensity of the stain (1-3) to achieve a composite score. Differences between 
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3A. Review of Literature 
3A.1 Introduction 
The past decade has seen tremendous development in disease modeling and 
generating accurate experimental models that mimic biological processes, from co-
culture techniques to 3D printed scaffolds and organoid culture [93-97]. Generating 
precise experimental models is essential for understanding basic biology, disease 
development, and therapy responses, but generating the complex biological 
environment of an organ to study development, or tumor to study progression and 
therapy, is nevertheless a challenging task. 
Over time, various tools have been employed to generate experimental models 
that can recapitulate human biology (or at least some of its properties). Conventional 
cultures have included growing transformed cells derived from biological tissues in 
monolayer cultures. These are easy to culture and amenable to experimental 
modifications. Though these transformed cell lines allow study of human cancer cells, 
because they have spent years in vitro since establishment, they tend to acquire an 
undefined and complex mutational background [98]. Monolayer cultures are also two-
dimensional (2D) and do not represent the tissue architecture and cellular heterogeneity 
found in tissues or tumors of their origin [98, 99]. 
Animal models make for some of the drawbacks of 2D cultures since they include 
stroma, vasculature, and immune components. They can, however, be engineered to 
generate transgenic disease models to recapitulate pathogenesis using molecular 
biology tools and breeding strategies. Another experimental use of these animals is 
generating patient-derived xenografts or tumor xenografts. These models are extremely 
powerful but are also resource intensive and time-consuming to develop. Moreover, the 
genomic profile of animal models does not exactly march with human profiles [100]. 
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The first reports that described 3D culture systems discussed models that allow 
for long-term expansion of single mouse adult intestine [101], stomach [93], liver [102], 
and pancreas [102]. The first breakthrough experiments in the field of 3D culture were 
performed using Lgr5+ stem cells or intestinal crypt cells in 2009 [101]; this study 
demonstrated that stem cells could be used to generate stable, near-physiological 
epithelia when supplied with growth factors and proteins close to endogenous stem cell 
niche components [101].  
The idea of a system that recapitulates a holistic microenvironment of normal 
biology ex vivo while proving experimental ease and feasibility of cell lines lead to the 
development of 3D culture methods. Cellular behaviors in vivo depend on environmental 
signals and contacts with neighboring cells and the extracellular matrix. 3D cultures 
allow for these signals to some extent and hence serve as an experimental system 
closer to normal biology.  
Organoid 3D-cultures can be formed using a variety of source materials, from 
spheroids derived from sorted cells to tissue segments, to whole organ explants [96, 97, 
101, 103]. Due to the differences in source material used and the 3D environment and 
scaffold provided, there are differences in the types of cultures generated, and it is this 
diversity that poses a challenge to define these organoids. Although the definition of 
organoids is still evolving, for the purposes of this review, we use the term to address 
cultures that recapitulate in vivo architecture, maintain stem cells or progenitor pool, and 
multi-lineage heterogeneity. 
Several approaches used to study a broad range of developmental and cellular 
processes have been comprehensively covered in reviews elsewhere [103, 104]. Our 
focus herein is on the most recent developments in organoid culture for major organs 
and cancers, including representation of their microenvironments and stem cells (niches) 
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on an appropriate scaffold. We also present our views on their implications on the 
development and testing of therapeutics. 
3A.2 Perquisites to Organoid Generation: Where do we start? 
Organoids have become a powerful tool for research and are becoming common in 
everyday lab practice, but there are certain key pieces of information necessary to 
consider before organoid development. Paramount among these are the selection of 
appropriate sources of organ or cells (iPSCs, Adult SCs, Organ chunks, embryonic SCs, 
etc.) and appropriate protocols that employ necessary growth factors and morphogens. 
The correct matrices essential for multiple stages of organoid development must also be 
determined. Then, once organoids develop, media composition must be determined to 
maintain structure and retain the functional characteristics of the organ of intent. In the 
following sections, we discuss such considerations and how they affect the generation of 
organoids. 
3A.3 Source Tissue: Beginning decides the end 
Organoids can be cultured from embryonic stem cells (ESCs), adult stem cells (AdSCs) , 
human-induced pluripotent stem cells (hPSCs), and tissue fragments. Development of 
hPSCs and human embryonic stem cells (ESC) culture techniques in parallel to 3D 
culture systems has helped researchers recapitulate the successful differentiation and 
development of endodermal (lung, stomach, liver, small intestine) and ectodermal (brain 
and retina) tissues in vitro, and has opened up new avenues for further research (Fig. 
1).  
Recent attention has focused on using hPSCs or patient tissue samples via the 
process of reprogramming adult somatic cells into induced pluripotent stem cells (iPSCs) 
by ectopic expression of pluripotency transcription factors [95]. These cells are then 
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transformed into organoids by using the signaling pathways involved in modeling germ 
layer formation and induction of organ primordia,Wnt, EGF, Retinoic acid, and 
TGFβ/BMP. iPSC-derived organoids have been generated from brain [105], lung [95], 
intestine [106], stomach [107], eyes [108], and kidney [109]. Organoids have also been 
generated using adult stem cells or adult primary tissue and then expanded long-term in 
vitro. These studies also built upon the available knowledge of stem cell niche 
requirements and generated their media with a base composition of Wnt, RSPONDIN, 
EGF, and Noggin, and include mouse and human pancreas, liver, intestine, stomach, 
prostate, fallopian tube, and salivary gland organoids [110]. Such availability of different 
sources determines the necessary media components. 
 
3A.4 Importance of Matrix Selection 
Once selected, it is important to provide an appropriate microenvironment for source 
tissue. The most common 3D environment used in the formation of organoids are 
hydrogels, such as Matrigel, that contain gelatinous mixtures of extracellular matrix 
components, including laminin and collagen [111, 112]. For instance, a primary culture of 
pancreatic ductal cells has been made possible by seeding stem cells or tissue 
fragments in Matrigel as submerged cultures that support the growth of epithelial cell 
cultures [93], whereas long-term organoid cultures that include both epithelial and 
mesenchymal components have been successfully performed using an air-liquid 
interface method [93, 100]. This method uses collagen gel containing trans-well 
suspended in media and direct exposure to air. Tissues or cells are mixed with Matrigel 
and layered over the collagen, where they develop organoids. The first study to engage 
this method developed a primary mouse intestinal culture that allowed for sustained 
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intestinal proliferation and multi-lineage differentiation. Such cultures lasted from 30 to 
>350 days using neonatal tissue as starting material [113]. This allowed recapitulation of 
both the cellular myofibroblast architecture and the rigorous Wnt and Notch-dependent 
stem cell compartment. These organoids could then be transformed into their oncogenic 
counterparts by genetic manipulation [114].  
A recent study reported that matrix stiffness has an impact on organoid growth 
and stem cell signaling in intestinal organoids. The authors reported employing a 
synthetic scaffold design, using a polyethylene glycol backbone with a more consistent 
and chemically defined synthetic hydrogel that allowed stem cell expansion and 
organoid formation [115]. Similarly, artificial scaffolds can be created by attaching 
microenvironmental signals such as ECM components and cell-to-cell interaction 
proteins to an artificial scaffold [115]. Various techniques may be tried, such as 
microcontact printing, which directly deposits ECM onto a partially polymerized hydrogel 
substrate using soft lithography techniques [116]. Nutrition and gaseous exchange are 
two other aspects affected by the matrix. Human bronchial epithelial cells(HBECs) 
embedded within Matrigel, for example, organize into spheroids that contain cuboidal 
epithelial cells, whereas HBECs plated on top of the Matrigel layer self-organize into 
tubular structures that undergo branching and budding. 
3A.5 Media requirements and properties of generated Organoids 
 
Developmental biology studies have long revealed that the morphogen gradient decides 
cell fate during embryo development. 3D organoids have been used to intelligently apply 
that knowledge when deciding on which media components will be necessary for a 
specific organoid generation. We will further describe media requirements and the 
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rationale behind several organoids that have been developed and used for modeling 
disease. 
 
Brain Organoids  
3D brain tissues or mini brains can now be generated using pluripotent stem cells (PSC). 
These tissues, also called cerebral organoids, are created by first driving pluripotent 
stem cells to a neural progenitor lineage and then providing a supportive 3-dimensional 
microenvironment for them, where they can self-organize spontaneously into the early 
embryonic brain [117]. A recent study reported the successful formation of brain 
organoids from human pluripotent stem cells, comprising the timely amalgamation of 
several previously published methodologies to accomplish successful differentiation of 
PSC into neural progenitors and progress further down the neural lineage [105, 118]. 
Mototsugu Eiraku reported in 2008 a special 3 D culture condition that showed 
differentiation of embryonic stem cells into embryoid bodies and then into self-organized 
apicobasal polarized cortical tissue [119]. He used FGF, Wnt, and BMP factors to model 
his 3D aggregate cultures. Since then, multiple reports have built upon his methodology 
[97, 105, 117, 118, 120-122]. A more recent study reported the development of 
heterogeneous brain organoids, naming them “cerebral organoids.” They used a similar 
approach and differentiated embryonic cells to neuroectoderm and then incubated them 
in differentiation media in Matrigel, finally allowing them to grow and form cerebral 
organoids in differentiation media supplemented with retinoic acid as Matrigel droplets in 
a spinning bioreactor [117]. 
A recent report described a novel developmental model of 3D brain-like tissue by 
applying an interdisciplinary approach, involving seeding cells within a biomaterial 
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scaffold to assemble microstructural features representative of native tissue [118]. This 
technique sought to recapitulate the structural features formed during development of 
the forebrain cerebral cortex, including gray matter (containing cell bodies) and white 
matter (containing neuronal axons). The study used silk protein to design scaffold, which 
provided spatial separation of cell bodies and neural processes. This lead to the 
development of a suitable matrix for growth of 3D compartmentalized neuronal networks 
that could recapitulate the properties of the native cortex and to establish the suitable 
conditions for neural growth [105, 122]. 
Lung Organoids 
During embryonic development, the endoderm produces a primitive gut tube along which 
the lung, thyroid, and organs lining the gastrointestinal (GI) tract emerge. The lung arises 
from cells expressing the transcription factor NKX2.1 (TTF-1; Thyroid Transcription 
Factor 1) in the ventral wall of the anterior foregut endoderm [123]. Hence, current 
available protocols include discrete steps to differentiate human pluripotent stem cells 
(hPSCs) through an initial definitive endoderm (DE) specification, then the anterior 
foregut endoderm (AFE), and finally into ventral anterior foregut endoderm (VAFE) and 
NKX2.1 expressing lung progenitors [123, 124]. Each step uses stage-specific growth 
factors to recapitulate the signaling pathways involved in lung development. Of 
importance, since organoids develop from tissue-specific stem cells or progenitors, 
hPSC differentiation into these cell types has been employed as a strategy to develop 
organoids.  
Lung organoids are mostly derived from primary respiratory cells and cell lines [123, 
125]. A recent study demonstrated that primary basal cells harvested from mouse and 
human lungs could self-organize into organoids, called tracheospheres or 
bronchospheres, when cultured in a 3D ALI [125]. These organoids are derived from 
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basal cells expressing p63 and NGFR, which proliferate to establish a layer of basal 
cells in a spherical organization, and that are covered on the luminal side by a second 
layer of a differentiated goblet and ciliated cells. 
Thus far, two studies have reported the generation of lung organoids in vitro from 
hPSCs. The first showed that purified Carboxypeptidase M (CPM) expressing cells in 3D 
conditions, supplemented with alveolar-related growth factors and human lung 
fibroblasts, produced alveolar epithelial spheroids. These spheroids contained cells 
expressing NKX2.1 and CPM, as well as differentiated cells that stained positive for 
AQP5 (Aquaporin 5) and SFPTC (Surfactant Protein C), markers of type 1 and 2 
alveolar epithelial cells (AEC1s and AEC2s), respectively [126, 127].  
The second study performed a step-by-step differentiation of hPSCs and reported 
multi-lineage organoids with epithelial and mesenchymal components. By stimulating the 
Hedgehog (HH) signaling pathway during spheroid generation, the authors could 
enhance NKX2.1 expression and expand spheroids in media containing FGF10 [123, 
126]. This allowed VAFE spheroids to grow into more complex structures that the 
authors called human lung organoids (HLOs). HLOs persisted in culture for over 100 
days and developed organized proximal airway-like epithelial tubules containing 
numerous cell types found in the native airway epithelium, including basal, ciliated, and 
club cells and that were surrounded by smooth muscle actin (SMA)- expressing 
mesenchymal tissue maintaining early bi-potent alveolar progenitor cells [123, 126, 127].  
In our lab, we explored these principles and generated lung organoids from genetically 
engineered mouse model with mutant KRAS and p53 deletion. We used a media 
composition that favors maintenance of stem cells and lung development by including 
factors such as FGF4, Noggin, and CHIR99021 (Glycogen Synthase Kinase 3 Inhibitor). 
These organoids generate histological structures similar to lung tumor and proved to 







Mammary acini contain extensive stromal and extracellular matrix compartments, the 
composition of which changes depending on signals such as growth factors and 
hormonal changes. Even monolayer cultures of mammary epithelial cells can form 
functional tubular structures when provided with the required environmental cues; for 
example, upon transplantation into the gland-free fat pads of mice [128]. It would be 
logical to infer that either the systemic factors or cellular microenvironment that 
surrounds the mammary epithelial cells confer the cues that drive functional 
differentiation of mammary epithelial tissue, suggesting the importance of providing a 
matrix to the cells in culture that resembles their biological ECM. Michalopoulos and 
Pitot (1976) were the first to use floating collagen gels to provide an extracellular 
environment to hepatocytes that could maintain their functional and morphological 
identities in culture for a short period [129]. Emerman and Pitelka further adapted this 
idea in the 1970s, and in 2013, Mroue and Bissell cultured mouse primary mammary 
epithelial cells that retained functional differentiation using both floating collagen-I (Col-I) 
gels and laminin-rich ECM gels (lrECM) [128, 130]. Mammary epithelial cells grown on 
floating collagen gels were found to reorganize and form secretory structures that 
express milk proteins de novo.  
Another observation made by Mroue et al. highlighted the significance of the 
composition of ECM provided in deciding the fate of cells in culture [130]. They reported 
that mammary organoids, when cultured on floating collagen gels, contained mammary 
epithelial cell (MECs) clusters, which exhibit basoapical polarity and cellular junctions, 
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and expressed the milk protein β-casein. These lacked expression of whey acidic protein 
(WAP) and did not form luminal alveolar structures, both essential features of the 
mammary gland [130].  
In a recent report, Linnemann et al. published alternative 3D culture conditions for 
the expansion of TDLU-like structures (Terminal Ductal lobular Units) from primary 
human cells [131]. The advantage of this method is that it includes conditions that 
support the growth of single cells at high efficiency. Its drawbacks are that it incorporates 
chemical agents (Rho-associated protein kinase inhibitor, forskolin) and serum that 
perturb intracellular signaling in nonphysiological ways. The relative merits and failings 
must be carefully considered before deciding the appropriate model system to use in the 
future study. 
Liver Organoids 
Two epithelial cell types, hepatocytes, and ductal cells, chiefly compose liver [132]. 
Hepatocyte-like cells have been generated by differentiating human embryonic stem 
(hES) cells and human induced pluripotent stem (hiPS) cells. However, because of the 
genetic and epigenetic aberrations that occur during the reprogramming process [133, 
134], the use of these models for translational research and regenerative medicine [135] 
remains limited. Generation of liver organoids overcomes these limitations; the 
organoids are generated by using the Wnt, BMP, RA, HGF, and FGF signaling pathways 
that regulate the embryonic development of the liver. 
Liver organoids were generated by mixing stem cells and/or tissue fragments 
with Matrigel and providing growth factors like EGF, HGF, FGF, and RSPO1. Such 
conditions allowed liver cells to self-organize into organoids resembling embryonic liver 
buds [136]. These organoids were Keratin positive and expressed progenitor cell 
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markers. The authors also reported that the generation of human liver organoids 
requires inhibition of TGFβ signaling. Replacement of Notch and RSPO by 
dexamethasone and BMP also allowed differentiation of these organoids into 
hepatocytes [136]. 
Pancreatic Organoids 
Two functionally distinct compartments make up the pancreas: ductal and acinar cells 
consist of the exocrine compartment, and the Islets of Langerhans make up the 
endocrine compartment. The genes and molecular pathways regulating the embryonic 
development of the two compartments are evolutionarily conserved and include FGF, 
HGF, Wnt, BMP, RA, and TGFβ. These pathways promote survival, proliferation, and 
migration of the progenitor pools that generate these two distinct compartments [93, 101, 
102, 137, 138]. Developmental studies and knowledge acquired from 3D cultures of the 
stomach and intestine allowed researchers to culture, expand, and differentiate mouse 
and human primary pancreatic tissue [101-103]. Providing an ECM and a 
microenvironment that includes growth factors essential during development of pancreas 
(Noggin, EGF, FGF and R-spondin-1(Rspo1)) is necessary for the long-term expansion 
of the adult pancreatic tissue in these 3D culture systems [102]. Using a similar 
approach, we developed murine pancreatic organoids from wild-type C57BL/6 murine 
pancreas which show histology similar to pancreatic ducts (Fig2.). A similar approach 
was also used to generate models to study pancreatic tumors and for which tumor 
organoids were generated from KC (Kras;PdxCre) and KPC (Kras;p53;PdxCre) 
autochthonous animal models for PDAC and were shown to histologically represent 
PDAC progression. 
Another study used neonatal wild-type C57BL/6 mice pancreatic tissue to 
generate organoids by the air-liquid interface culture method. These grew progressively 
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for more than 30 days as cystic structures carrying an epithelial layer and surrounded by 
fibroblasts [139]. α-smooth muscle actin–positive (SMA+) stromal cells were observed in 
association with these cystic epithelial organoids, which could be readily infected with 
adenovirus and were predominantly comprised of E-cadherin–positive (E-cad+) and 
Pdx1+ ductal epithelium with PCNA+ proliferating cells. [93, 140]. Somatostatin and 
insulin were also found to be expressed in rare, islet-like regions not always associated 
with ductal structures; sporadic immunoreactivity was also reported for glucagon and 
amylase occasionally. 
Intestinal organoids 
A submerged Matrigel model [101] allowed a culture of Lgr5+ cells or crypt fractions to 
be cultured into exclusively epithelial organotypic intestinal structures, also referred to as 
enteroids. Growth factors that simulate the paracrine signaling environment surrounding 
stem cells were supplemented in a media concoction for these enteroids, and 3D mouse 
and human organoids were generated [101]. Intestinal organoid or enteroid generation 
by this method requires Wnt stimulation with Wnt3A, epidermal growth factor (EGF), the 
BMP antagonist Noggin, and the Wnt agonist R-Spondin1 to be supplemented in the 
media [141]. Another recent method uses collagen-based, air-liquid interphase to 
generated 3D organoids which incorporate epithelial and mesenchymal components 
[142]. This system uses collagen and Matrigel together to grow organoids on air-liquid 
interphase, without the requirement of exogenous growth factors, and the resulting 
organoids were found to contain both epithelial and mesenchymal compartments and 
could be cultured for >60 days [143]. Primary intestinal and tumor organoids have been 
generated using both these methods and are currently being used for a variety of 
applications, from toxicology studies to drug screens and disease modeling [143].  
Epithelial enteroids propagated from mouse or human Lgr5+ cells or intestinal 
crypt fractions follow an easy-to-follow method of generation and expansion. Enteroids 
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typically constitute cystic epithelium with an inward-facing apical side and a progenitor 
pool containing crypt-like invagination [144]. All intestinal lineages have been observed 
in these cultures, which could be serially passaged and expanded. To enhance 
efficiency and include multiple biological parameters, several refinements have been 
made to this system, including Wnt3A withdrawal used to facilitate differentiation; the 
use of the Rho kinase inhibitor Y-27632 to avoid anoikis during tissue preparation, 
passaging and revival; using GSK3β kinase inhibitors and valproic acid to promote a 
stem-like state; and myofibroblast feeder layers to replace Wnt and R-spondin from 
medium [143]. Isolation of these enteroids follows a general scheme of mincing tissue or 
intestine and subjecting it to enzymatic digestion. The digested fraction is centrifuged, 
and intestinal crypts are isolated from it. These crypts are then embedded in Matrigel 
and seeded in submerged cultures [101].  
Ovarian and Fallopian Tube Organoids 
Fallopian tube model systems have traditionally facilitated ovarian development and 
ovarian cancer studies, and a similar trend was followed in 3D culture systems. Recent 
studies have demonstrated the existence of adult stem cells in the human fallopian tube 
epithelium that gives rise to differentiated epithelial cells in complex 3D organoids in vitro 
[145]. These organoids were reported to recapitulate the in vivo tissue architecture; they 
could depict growth and be maintained in culture long term. The culture protocol and 
growth conditions are similar on a gross scale to the intestinal tract, skin, liver, and 
ovary. Active Wnt signaling works towards maintaining the stem cell population in these 
organoids, achieved by activating Wnt target genes Lgr4, 5, and 6, all of which are a 
subfamily of leucine-rich, repeat-containing G protein-coupled receptors that can 
strongly amplify Wnt signals. The R-spondin family of proteins also acts as an Lgr 
receptor agonist. Similarly, the growth capacity of organoids is modulated by Wnt3A and 
R-spondin-1 (RSPO1) [145]. This organoid model faithfully mimics the normal physiology 
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and anatomy of the human fallopian tube and provides a platform for future 
investigations into the regulatory mechanisms involved in its cellular renewal and 
pathology. Overall growth rates for these organoids during long-term culture remained 
constant, with passaging every 2–3 weeks. This method yielded expandable, stable 
organoid cultures in all healthy tissue samples, with minimal variations in sphere 
formation potential and growth rate between donors or between distal and proximal tubal 
regions 
Prostate Organoids 
The prostate gland produces seminal fluid in the male reproductive system and is 
composed of a pseudostratified epithelium of luminal, basal and rare neuroendocrine 
cells. Additionally, prostate development and homeostasis, as well as prostate cancer 
initiation and progression, requires androgen receptor (AR) signaling [146]. Most in vitro 
studies are performed using cell lines, and most of these do not have an intact AR 
signaling pathway, making them poor models to represent healthy prostate and cancer 
tissue [146, 147]. Lack of suitable in vitro model systems is an obstacle for prostate 
cancer research. Although robust in vivo models are available, these are often 
expensive, time-consuming, and technically daunting.  
Another study by Chua et al. recently demonstrated the development of 
organoids from sorted luminal cells, but these 3D cultures with limited growth potential 
[148]. Although these were AR-responsive, the medium used in this study included 
undefined components like fetal calf serum and had a plating efficiency of 0.2% to 0.3% 
[147, 148].  
Drost et al. developed a testosterone-responsive prostate organoid culture 
system by adapting and optimizing the culture conditions previously employed to 
establish mouse and human colon and intestinal organoid cultures. Different compounds 
and growth factors, including epidermal growth factor (EGF), Noggin, and R-spondin 1, 
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were added to the generic organoid medium to allow for the establishment of long-term 
mouse and human prostate organoid cultures. These submerged prostate organoid 
culture systems contain multipotent progenitor cells in both the luminal and basal 
lineages that can be propagated long term. AR signaling is indispensable for organoids 
to functionally recapitulate prostate and was maintained in these organoids. This study 
concluded that organoids derived from human or mouse prostate cancer recapitulate 
genetically and phenotypically the tumor from which they were derived [147]. 
This method was further adapted by our lab to generate prostate and prostate 
cancer organoids from mouse tissues (Fig. 2). The main procedure involves dissection 
and digestion of tissue, followed by subsequent embedding, plating, and organoid 
passaging. We plated organoids are plated in Matrigel and cultured them in a defined 
prostate culture medium, after which they were sub-cultured and frozen. These 
organoids can be cryopreserved once established and are genetically and 
phenotypically stable. Prostate tumor organoid media includes DMEM/F12 
supplemented with B27, N-acetylcysteine, EGF, Noggin, R-spondin 1, A83-01, and DHT 
[147, 149].  
3A.6 Limitations: Need for Intervention 
 
The potentials organoids hold for future study and use are innumerable, but they present 
some limitations, as does any technology. The organoids established so far need to be 
characterized and studied to the extent that exact recapitulation of in vivo development 
is possible. Tissue maturation is one of the limitations associated with retinal and 
cerebral organoids, where early events display intact organization, but the organized 
tissue fails to develop into a functionally mature organ. However, intestinal organoids 
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produce Lgr5+ stem cells, implying movement towards a mature intestine [101]. One 
solution to the maturation problem may be by growing a mature organ followed by 
transplantation. Another limitation of organoids is non-vascularization due to limitations 
in nutrient supply, which may be solved by spinning bioreactors that provide a better 
nutrient exchange. Vascularization may also be achieved by co-culturing with endothelial 
cells that can generate vascular-like networks. Some researchers have generated hybrid 
cultures with organoids to incorporate different cell types to generate more insightful 
models.[150]  
Another limitation to organoid cultures is the limited presence of stromal 
components, including immune components, and this hinders organoid use in modeling 
inflammation and drug penetration studies [151]. Organoid cultures are also 
heterogeneous with no reliable means of synchronizing size shape and viability. This, 
unfortunately, leads to complications in data analysis and study design. Although all 
these limitations stand in the way of organoid applications, they can be overcome by a 
better understanding of ECM components and live cell imaging techniques that facilitate 
the analysis of the co-cultures or hybrid cultures of these organoids. 
3A.7 Prospective application: Making the most of tremendous tool 
Normal organoids derived from stem cells and specific organs can be used for their 
molecular impact on organogenesis study. Here we discuss different areas of biological 
science research that organoids have applications in. (Fig. 3).  
Organoid developed for tissue modeling 
Organoids hold an advantage over traditional techniques to solve unanswered questions 
in developmental biology because of the accessibility of model systems, especially for 
human models. For example, the unique division mode of neural stem cells has been 
studied using human brain organoids [105, 117, 151]. Similarly, the differences in tissue 
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morphogenesis and timing between humans and rodents have been studied using 
retinal organoids. Furthermore, organoids may be used to study processes that differ in 
model organisms and humans, such as GI tract development, and to model adult 
homeostasis. Specifically, the role played by the crypt niche in self-renewal and 
differentiation of stem cells has been studied using intestinal organoids. Regenerative 
events in adult organs, such as liver and stomach, have also been closely recapitulated 
by organoids derived from adult progenitors.  
Organoids developed for regenerative medicine 
Organoids also provide an alternative for cell and whole organ transplantation by 
providing autologous tissue. Organ transplant procedures with high demands and low 
success rates, such as renal transplants, may be improved using corresponding 
organoids. Successful transplantation of kidney organoids in adult mice has been 
already achieved by Taguchi et al., paving the way for a promising future for organoid 
transplantation [109, 152]. Stem cell therapies are being aided by retinal organoids in 
clinical trials to replace degenerating cell types. On similar lines, intestinal organoids are 
also under investigation to treat damaged and diseased colon.  
Organoids used for therapy response in cancer and other pathologies 
The failure rate of traditional models of therapy testing translating to patient treatment 
regimens has launched a hunt for more reliable and physiological models, such as 
patient-derived organoids for drug screenings and drug discovery studies. Yin et al. 
recently reported the use of primary intestinal organoids for modeling retroviral infection 
and antiviral therapy in an attempt to address the lack of potent antiviral therapies [153]. 
In another study, Ogawa et al. used patient-derived cholangiocyte organoids to correct 
the misfolded CFTR protein (cystic fibrosis transmembrane conductance regulator) 
[154].Using a similar strategy, Schwank et al. used CRISPER/Cas9 to repair the function 
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of CFTR in intestinal stem cell organoids. Such studies highlight the utility of organoids 
in disease modeling and therapeutic testing [155].  
Additionally, Huang et al., in a recent study generated pancreatic ductal 
organoids and induced mutations in them to successfully model pancreatic ductal 
adenocarcinoma. They then used these organoids to test the therapeutic efficacy of a 
histone methyltransferase inhibitor, working along the idea of disease modeling and 
therapy [156]. Skardal et al. established 3D liver organoids to model colorectal cancer 
metastasis and were able to test therapies on metastatic disease [150]. Van de Wetering 
et al. established tumor organoid cultures from 20 colorectal carcinoma patients 
representing most genetic subtypes of colorectal cancer generating a living biobank 
[157]. In these and other examples, we can see that organoid technology provides an 
opportunity to bridge the gap between patient-derived cell lines and xenograft mouse 
models, generating a link between cancer, genetic, and patient trials to make possible 
better and personalized therapy designs. All these studies suggest that 3D organoids 
models are still developing but have immense potential for modeling various diseases 
and use in therapy design. 
3A.8 Conclusions and Perspectives: Towards modeling accurate homeostasis and 
disease 
 
Organoid cultures are accessible and physiologically relevant models to study biology. 
They can be derived from multiple sources, and they maintain stem cell or progenitor 
population. [93, 103, 140, 144, 158]. These models are robust in recapitulating in vivo 
tissue biology and have shown to be reliable in testing therapeutic response. They have 
the capacity to serve as a platform for translational research and high throughput 
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preclinical screenings. Organoid technology has worked successfully with current 
research methodologies and found its niche.  
More development will be seen in 3D organoid systems that will compensate for 
the limitations the technology still suffers, however. Despite this, we hope to see the 
extensive use of organoids in many more avenues. Patient-derived organoids provide an 
opportunity to develop personalized treatment regimens for patients since biopsies can 
be an excellent source of disease site tissues and normal tissues for deep sequencing. 
This would, in turn, reveal causal mutations and phenotypic profile to generate 
therapeutic approaches tailored to each patient. Once organoids from patients are 
generated, they can be used to test efficacy or resistance to proposed regimens. 
Additionally, organoids generated from healthy tissues can be used to weed out toxicity 
and other undesired effects of the proposed therapy.  
Organoid studies are being used for disease modeling for developmental 
disorders, cancer, degeneration, and other infectious diseases [142, 144, 150, 153, 155, 
159-162]. This may also be achieved by introducing patient mutations in human PSCs, 
using genome-editing techniques, by generating organoids or inserting mutations directly 
into organoids. Organoids are also being employed for screening drugs, testing for 
efficacy and toxicity by modeling different degenerative conditions such as liver fibrosis 
or cystic kidney diseases where effective treatment regimens are required. If successful, 
this approach could lead to a reduction of the use of animal testing, which would be 
reserved only for studies requiring whole-organism readouts.  
Organoids have found their place in everyday research and to date have 
significantly supplemented our knowledge and ability to model diseases. We have seen 
an exponential increase in their usage and application since the first introduction. Their 
reliability, robustness, and amenability for research have yielded enormous downstream 
applications, highlighting their role in recapitulating homeostasis and diseases. These 
79 
 
characteristics make organoids extremely exciting and promising technology that holds a 









3A.9 Figures and legends 
 
Fig. 3.1 Representation of the organoids generated, and the media compositions 
required: These hosts of organoids have been generated from different source 
materials, including iPSCs, adult stem cells, embryonic tissues or cells and adult tissue 
explants. Different media compositions are required for each type of source material 
used and the type of differentiation to be achieved (organ-specific), which is elaborated 
in detail in the text. Specifically, cerebral organoids need a stepwise incubation of 
pluripotent stem cells in neural induction media (DMEM-F12, N2 supplement, GlutaMAX 
supplement, MEM-NEAA, heparin) followed by cerebral induction media (DMEM-F12, 
Neurobasal medium, N2 supplement, insulin, GlutaMAX supplement, MEM-NEAA, 
penicillin-streptomycin, 2-mercaptoethanol, B27 supplement). Mammary organoids can 
be developed from tissue fragments using media composed of DMEM/F12, FBS, ITS 
Selenite media supplement, FGF2, FGF10 for mouse or EpiCult B medium 
supplemented with hydrocortisone, insulin, FGF10, HGF for humans. Liver organoids 
can be generated by mixing tissue fragments in DMEM/F12 media supplemented with 
FBS, EGF, RSPO1, FGF, HGF, Nicotinamide, and insulin. Pancreatic organoids need 
a media comprising of DMEM/F12, B27 supplement, Nicotinamide, Noggin, EGF, FGF, 
and RSPO1. Ovarian organoids are generated by seeding fallopian epithelial cells in 
Matrigel with media comprising AdDMEM/F12, Wnt3A, RSPO1, HEPES, GlutaMAX, 
B27, N2 Supplement, EGF, noggin, FGF10, Nicotinamide, Y-27632, and SB431542. 
Prostate organoids need a media containing DMEM/F12, B27 Supplement, N-
acetylcysteine, EGF, Noggin, RSPO1, A83-01, and DHT. Kidney organoids need a 
media containing DMEM high glucose, FBS, NEAA, GlutaMAX, Heparin, APEL media, 
FGF9, SB431542, and CHIR99021. Gut or intestinal organoids need a media 
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composition of DMEM/F12, FBS, B27, EGF, RSPO1, Noggin and Wnt. Specific 
cultivation of stomach organoids needs media composition same as intestinal organoids 
with the addition of FGF. Lung organoids can be generated and grown in media 
containing DMEM/F12, FBS, B27, N2 Supplement, GlutaMAX, FGF4, Noggin, 
SB431542 and CHIR99021. 
Abbreviation used are: Y-27632:ROCK inhibitor, SB431542:TGF-β R Kinase Inhibitor IV, 
ITS: Insulin Transferrin-Sodium, NEAA: Non Essential Amino Acid Culture Supplement, 
EGF: Epidermal Growth Factor, RSPO1: R-spondin-1, Wnt3A: Wingless-Type MMTV 
Integration Site Family Member 3A, T3: Triiodothyronine, FBS: Fetal Bovine Serum, 
FGF: Fibroblast Growth Factor, HGF: Hepatocyte Growth factor, DMEM/F12: Dulbecco's 
Modified Eagle Medium: Nutrient Mixture F-12 , DHT: Dihydrotestosterone , CHIR99021: 

















Fig. 3.2 General scheme of generating organoids and representative figures of 
organoids generated by our laboratory: 
The flowchart represents the scheme of organoid isolation which is modified for each 
organoid according to the organ or tissue architecture to generate submerged organoids. 
Briefly, desired source tissue (progenitor cells or tissue fragments) is isolated from the 
host by mincing the organ and then subjecting it to enzymatic digestion. The digestion 
media composition and the digestion protocol are decided depending on the host tissue. 
The digestion media usually contains a mixture or Dispase and Collagenase or 
Collagenase alone and can take from 30 mins to 4-6 hours. Following digestion, the cells 
are mixed in the matrix (like Matrigel or collagen) suitable for the desired organoids. A 
suitable media is overlaid once the matrix solidifies. Once generated, organoids grow in 
ductal like morphologies like their human counterparts. Picture panels depict the 
microscopic pictures of organoids generated in our lab from normal and cancerous 
prostate and pancreas as well as lung cancer organoids (upper panel) along with 
hematoxylin and eosin stained sections of the same (lower panel) depicting the 
difference in the organization of cells in each of these organoids. Figure magnifications 















Fig.3. 3 Potential applications of organoids generated:  
The figure presents prospective applications of organoid culture tool for the 
advancement of biological research. The arrows in the figure represent the flow of 
information from tumor modeling, disease modeling and developmental biology studies 
towards therapeutic interventions. To expand since organoids, represent tissue 
homeostasis in vitro, they can be used to model pathologies by inducing desired 
mutations or exposing them to necessary stimulus or pathogens. Following which the 
pathogenesis and disease development can be studied. Such studies facilitate further 
research to study drug response or generate organoids directly from patients to device 
personalized therapeutic strategy as represented by the arrows emerging from disease 
modeling bubble. Similarly, modeling cancer initiation and progression in organoids can 
facilitate therapeutic response studies and the discovery of new oncogenic proteins or 
antigens that can be targeted illustrated by arrows emerging from the Tumor modeling 
bubble. Additionally, lineage tracing studies or organ development studies using 
organoids have immense potential for the field of organ replacement therapy and can 
help neoantigen discovery for cancer research (arrows emerging from developmental 
biology studies bubble). The dashed arrows represent the overlapping domains amongst 














3B Generation and optimization of organoid cultures  
3B.1 Background and rationale 
 
3D culture or organoid cultures provide a robust experimental model that simulates in 
vivo biology and pathologies and are becoming the popular choice of model to study 
therapy response (Kaushik et al. 2018). These are cell-derived models that simulate 
endogenous cell organization and architecture hence enable cell behavior, 
pathobiological and drug response research. Organoids can be generated from very little 
source material like biopsies, circulating cells isolated from patients granting an 
opportunity for developing personalized therapy. Further their potential applications in 
the fields of disease modeling, gene editing, organogenesis, and transplantations makes 
them instrumental research tools. For these reasons, many studies have attempted to 
setup cryopreserved biobanks of human organoids as a resource for researchers and 
clinicians. 
 In 2009 Sato et al. demonstrated that embedding LGR5
+
 intestinal stem cells 
into a 3D matrix yield self-organizing organotypic structures revealing a single adult 
stem cell has the potential to generate organoids [163]. R-spondin1, EGF and noggin 
were shown to be critical to mimic the in vivo stem cell niche vital for an organoid 
generation in this study. Further may studies utilized similar niche factor 
supplementation to create organoids for other multiple mice and human epithelia, 
including colon, liver, pancreas, prostate, stomach, fallopian tube, taste buds, salivary 
glands, esophagus, lung, endometrium, and breast [92]. Many studies since have 
reported stable long-term expansion and cryopreservation of organoids; this makes 
organoids attractive tools considering lack of available source tissue is a hindrance in 
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cancer research. Organoids can also be genetically modified and remain genetically 
and phenotypically stable allowing for a wide range of applications in cancer research. 
Huch et al. published the first study reporting conditions for in-vitro expansion 
of adult bipotent pancreatic progenitor cells through Lgr5/R-spondin axis [164]. A 
crucial component of their culture medium is the Wnt agonist RSPO1, the recently 
reported ligand of Lgr5 and its homologs. Wnt signaling is vital for pancreatic 
development during embryogenesis but is inactive in adult pancreas [165-167]. An 
injury to adult pancreas results in reactivation formation of new pancreatic islets in a 
similar fashion as embryonic pancreas where multipotent progenitor cells give rise to all 
pancreatic lineages (acinar, duct and endocrine) [168-170]. Partial duct ligation (PDL) or 
acinar ablation studies have shown that duct cells can proliferate and differentiate 
towards acinar, duct and endocrine lineages, suggesting presence of pancreatic 
progenitor pool within ductal cells in adult pancreas [139, 171-175]. Wnt-Lgr5-Rspo 
signaling axis can be exploited to create culture conditions that enable long-term 
expansion of adult pancreatic duct cells, with the ability to differentiate towards both duct 
and endocrine lineages in the presence of proper signals [164]. 
3D organoids have also been developed from malignant mouse and human 
pancreatic tissues and utilized to investigate PDAC pathogenesis [93, 137, 176]. 
Organoids derived from wildtype and genetically modified mouse models PDAC 
recapitulate disease progression with close physiological relevance in vitro. 
Additionally, organoids derived from mouse and human PDAC tissues generate PanIN 
like lesions and progress to invasive PDA, following transplantation. Whereas, organoids 
from wild-type mouse normal pancreas regenerate normal ductal architecture [137].KC 
(Kras; PdxCre) and KPC(Kras; p53; PdxCre) mouse models are well established 
genetically engineered autochthonous mouse models of PDAC and have been used to 
generate murine PDAC organoids to study therapeutic response [137, 177]. 
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Several studies have reported the development of organoids from stem cells that 
retain progenitor cells in different organs [102, 163, 164, 178]. Murine pancreatic 
progenitors grow into 3D complex organoidal structures that spontaneously undergo 
pancreatic morphogenesis and differentiation when embedded in Matrigel and presence 
of appropriate medium composition [179]. Recapitulation of in vivo niche signaling 
interactions is necessary to enable expansion of progenitors, which is achieved by active 
Notch and FGF signaling [179]. Single isolated adult mouse pancreatic progenitors 
which belong to ductal lineage have the potential to expand and form organoids in 
Matrigel-based 3-D culture system [102, 179]. Pancreatic organoids maintain Lgr5 
expressing population and can differentiate to endocrine cells [102]. Human and mouse 
pancreatic organoids allow expansion and the generation of progenitor cell 
subpopulation. high aldehyde dehydrogenase activity (ALDHhi) and expression of 
pancreatic progenitor markers (PDX1, PTF1A, CPA1, and MYC) are maintained in 
pancreatic organoids [102, 164]. 
PDAC organoids have been used to study therapy response [159, 180]. Human 
patient-derived PDAC organoids carry patient specific and histopathologic 
characteristics and can be used to study the etiology of patient tumor and therapy 
response. Genetic and structural features of primary pancreatic adenocarcinoma tumors 
are well represented by human PDAC organoids [181]. 
We decided to generate 3D culture/organoids from mouse models of pancreatic 
cancer to study therapeutic strategies and PDAC pathology. We utilized tumors resected 
from KC and KPC mouse models and wild type mice to generate our organoids. We 
standardized our protocol and culture conditions by building on previously established 
culture conditions reported in Sato et. al. We also created organoids from adjacent 
normal and tumor tissues obtained from PDAC patients to test the effect of our therapy 
in clinical samples. 
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Apart from establishing Pancreatic organoids we also developed lung and 
prostrate organoids in our lab for further utilization in metastatic as well as other studies. 
In this part of my thesis, we report the generation or organoids and optimization of 
experimental protocols for normal and tumor organoids. We also report the maintenance 
of cancer stem cells in our organoids and standardize a method to track and analyze 
organoid growth and therapeutic response. We use these standardized protocols and 








3B.2.1 Generation of Organoids 
3B.2.1a. Murine Pancreatic Organoids 
 
Pancreas or pancreatic tumors were resected from wildtype C57BL/6, KC, and KPC 
mice. The resected tissue was mechanically minced to a size of approximately one 
millimeter. Minced tissue was digested with a mixture of collagenase XI and dispase in 
DMEM media with the addition of 1% FBS for KPC organoids. A period of 30 minutes to 
one hour was enough for digestion of wild-type pancreas whereas KC and KPC 
organoids required 1 hour to 3 hours to digest. During the period of digestion at 30-
minute intervals, an aliquot of supernatant from digesting tissue was observed under a 
microscope. After one and a half hour chains of cells could be observed in the 
supernatant under the microscope. These chains represent ductal cell population. The 
supernatant from this digest was taken for organoid culture, and the remaining digest 
was incubated again for further digestion. The supernatant was taken at several time 
points until we stopped seeing strings of ductal cells under a microscope. The 
supernatant was then washed and embedded in growth factor reduced matrigel and 
seeded in 48 well plates.The seeded matrigel domes were allowed to set for 15 minutes 
in the incubator.  
 KC Organoids were supplied with complete AdDMEM/F12 medium 
supplemented with HEPES, Glutamax, penicillin/streptomycin, B27, N-acetyl-L-cysteine, 
epidermal growth factor (EGF). Although organoids formed in this media, we got a very 
low efficiency. Additional growth factor was added for an enhance efficiency namely, 
fibroblast growth factor 10 (FGF10), Nicotinamide, and A83-01 (TGFb inhibitor), Noggin, 
R-spondin. However, KPC and normal organoids needed supplementation with FBS for 
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initial establishment. A recent study reported tumor organoids to appear spherical under 
a microscope, whereas normal pancreatic organoids appear cystic (Seino et al. 2018). 
Once developed, our tumor organoids grew as single-cell-layered spherical ductal 
structures in vitro and developed more complex structures as the days progressed. Our 
normal organoids had the cystic appearance and did not gather morphological 
complexity in a culture like that of HC, KPC organoids (Fig.3.4a). 
 
3.B.2.1b Human pancreatic organoids 
 
Lack of available human patient tissues is a major hindrance to pancreatic cancer 
research. Human PDAC organoids have potential in providing ample research material 
for drug screening and a window for personalized therapy protocol development specific 
to the patients. Human tumor and adjacent normal samples were obtained from the 
surgery department and subjected to mechanical and digestion similar to murine 
organoids with addition of Primocin and A83-01 in digestion media. The digestion and 
seeding protocol was similar to murine organoids. Human PDAC and normal like 
organoids needed a further enriched media with the addition of Primocin, gastrin in 
complete media for both tumor and normal and PGE2 in normal organoids. One 
representative figure from the 4 successfully generated lines of patient PDAC organoids 
has been provided in Fig. 2.1b. We could also generate organoids from MUC4 knockout 
mouse model for PDAC developed in our lab (Fig.2.4C) 
 
3.B.2.1c Lung organoids 
 
Lung organoids have typically been derived from isolated progenitor cells from 
dissociated lung tissue (Hogan et al. 2014). Basal cells exist in the pseudostratified 
93 
 
mucociliary epithelium that lines mist of the conducting airways in the lungs and expands 
to regenerate the lungs upon injury in adult mouse (Pardo-Saganta et al. 2015). 
Organoids that represent the mucociliary epithelium of the lungs are generated by 
seeding isolated basal cells in a matrigel based system (Roch et al. 2011; Tata et al. 
2013). Isolated humans pluripotent stem cells (). Bronchioalveolar stem cells (BACs) are 
club cells that exist in distal bronchioles and have the potential to differentiate into both 
type 2 Alveolar cells (Stem cells) and airway cells. Organoids that contain both alveolar 
cell and airway cell lineages can be derived from isolated BACs (). Both the processes 
have strong requirement of EGF signaling to enable growth. The process of stable 
human lung organoid development requires stepwise differentiation of pluripotent stem 
cells from a definitive endoderm state to anterior foregut endoderm and finally to NKX2.1 
expressing lung progenitors(). Activation of the hedgehog pathway followed by exposure 
to FGF 10 signaling allows differentiation to an anterior foregut endoderm state, and 
further exposure to differentiating factors like BMP signaling allows differentiation into 
lung progenitors. To generate organoids from a mixed population of cells and to get 
organoids that represent both proximal and distal epithelium we adapted from the 
method developed by Biana et al. Lungs from C57BL/6 wildtype and KA (Kras
G12D
; 
AdCre) and KPA(KrasG12D; p53R172H+ AdCre) were resected and subjected to mechanical 
and enzymatic digestion similar to pancreatic tissue as reported before. 30 minutes of 
digestion was enough to allow digestion sufficient for an organoid generation (large 
clumps of cells were not visible in the supernatant from digesting mixture). The 
supernatant was then seeded in low attachment plates in presence of BMP, TGFb and 
Wnt activators, FGF and RA activators allowing expansion of stem cell and progenitor 
populations. This lead to formation of lung spheroidal structures which were them 
embedded in Matrigel. Once matrigel solidified the media was replaced to Wnt, FGF, 
cAMP and glucocorticoids containing media to enable growth of lung organoids. We 
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successfully generated lung organoids representing two different cancer grades (KA and 
KPA) (Fig. 2.4D) 
3.B.2.1d Prostate organoids 
 
Development, homeostasis of prostate and prostate cancer all require active AR 
signaling (Pienta KJ et al. 2008). Cell line cultures used for prostate cancer study do not 
have an intact AR signaling pathway. Prostate organoids can be generated by isolated 
luminal cells, which represent one of the progenitor populations in the prostate (Chua CV 
et al. 2014). Prostate organoids derived from digested prostate tissues contain 
multipotent progenitor cells from both luminal and basal lineages and active AR signaling 
(Drost et al. 2016). Stable AR-responsive and progenitor pool containing prostate 
organoid expansion require EGF, Noggin, and R-spondin signaling along with AR 
signaling (Drost et al. 2016). We adapted previously published protocols for prostate, 
pancreas and intestinal organoids and developed murine wildtype prostate and prostate 
cancer organoids. Prostate and prostate tumor tissues from wildtype C57BL/6 and Pten 
conditional knockout mouse was carefully resected avoiding seminal vesicles, remaining 
urogenital system and fat tissue. The resected prostate was minced into small pieces of 
around one millimeter followed by enzymatic digestion with Collagenase type II. After 2 
hours of digestion supernatant from the digest was mixed with Matrigel and seeded as 
domes in 48 well plates. Once the matrigel solidified prostate organoid media comprising 
DMEM/F12, B27, N-acetylcysteine, EGF, Noggin, R-spondin 1, A83-01 and DHT was 
added to the matrigel domes. We successfully generated organoids from normal 
prostate and prostate cancer (Fig. 2.4E). 
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3B.2.2 Maintenance of progenitor cells or CSC pool in pancreatic cancer 
organoids. 
Organoids were stained for expression of several self-renewal and CSC markers to 
examine retention and expansion of CSC population in developed PDAC organoids. 
Common CSC and stem cell markers utilized in pancreatic cancer were used including 
OCT4, SOX2, CD44v6, ALDH1, ABCG2, CD133, ESA, and pEGFR to include multiple 
CSC subpopulation. The beautifully stained organoids confirmed the presence of CSC 
and self-renewal markers (Fig. 2.5). A recent publication revealed the presence of a new 
CSC population in PDAC called autofluorescent cells. These cells retain auto fluorescing 
riboflavin in their ABCG2 expressing vesicles and hence exhibit autofluorescence. We 
could observe the presence of this newly identified subset of CSC; autofluorescent cells 
in established organoids (Fig.2.5). 
 
3B.2.3 Tracking Growth and therapy response in organoids 
We used KC organoids for standardization of the protocols. We could track individual 
organoids over a span of several days to analyze the change in the size of the organoids 
over time (Fig. 2.6 a). Our studies revealed that KPC organoids grow significantly faster 
in culture compared to KC organoids (Fig. 2.6 b). This is an expected growth pattern 
since KPC mice develop more aggressive tumors as compared to KC mouse. This 
growth pattern also suggests that organoids retain their in vivo growth pattern in vitro. 
We could also perform drug treatment and follow organoids to analyze the change in 
organoids size due to therapy representing growth inhibition (Fig.2.7a,b,c). We use this 








Developmental pathways employed in embryonic development of pancreas are 
evolutionarily conserved [93, 137, 163, 182, 183]. Signaling pathways such as Wnt, 
BMP, FGF, HGF, EGF, RA and TGFb are some of the vital pathways responsible for 
generating a morphological gradient that allows development of the pancreas. The 
standard requirement to enable the growth of pancreatic 3D cultures is to supply factors 
to enable the functionality of these pathways since they promote proliferation, survival, 
and migration of progenitor pools [92]. To provide a supportive ECM which also allow 
cell motility we used matrigel as reported by several other studies. To supply necessary 
nourishment, we try multiple media compositions with limiting growth factor availability 
and find a difference in efficiency of organoids generation. This suggests a requirement 
of an enriched media for high-efficiency organoids generation but the possibility of 
utilizing a growth factor limiting media to facilitate the growth of organoids as per the 
need of the experiment. A recent study has reported limiting the availability of EGF and 
Noggin to allow enrichment of KRAS mutant and SMAD 4 mutant organoids [184]. 
Previous studies from other labs have reported the development of pancreatic tumor 
organoids that retain attributes of pancreatic ductal adenocarcinoma from duct cells 
isolated from neoplastic tissues [137]. We mince and enzymatically digest pancreatic 
tissues enough to isolate chains of ductal cells. 
Different enzymes and duration of digestion were required for tissues from 
different origins such as the normal murine or human pancreas, and KC, KPC, and 
patient pancreatic tumors. It is critical to achieving appropriate digestion of the tissue 
since too much or too little digestion would both lead to failure of the protocol. Over-
digestion damages the ductal cells whereas under digestion leaves them in clumps that 
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have cells from acinar and ductal cells and presence of acinar cells limits ductal cell 
growth. 
3B.4 Figures and Legends 
 
Fig. 3.4 Established KC, KPC ad Human PDAC organoids 
Organoids were generated from respective murine or human tissues following enzymatic 
digestion and matrigel embedding. After a week in culture murine organoids were 
observed under microscope and images were clicked. Human organoids were cultures 
for 3 weeks before the pictures were clicked. Organoids were subsequently paraffin 
embedded and sectioned. The slides were then stained with hematoxylin and eosin to 
observe structural morphology of the organoids. A) Microscopic and Hand E stained 
representative images of established mouse KC, KPC and wildtype organoids. B) 
Microscopic and Hand E stained representative images of established human PDAC 
organoids. C)Microscopic and Hand E stained representative images of established 
MUC16 Ko KPC organoids. D) Microscopic and Hand E stained representative images 
of Prostate Normal and Cancer organoids. E) Microscopic and Hand E stained 

































Fig. 3.5 CSC population is maintained in pancreatic cancer organoids 
Organoids were paraffin embedded and sectioned. The slides were then stained with 
respective fluorescently stained antibodies and DAPI to observe molecular expression. 
A) Immunofluorescent stained images of pancreatic organoids stained for CSC and self-
renewal markers CD44, ALDH1, ABCG2, CD133, OCT4, SOX2, ESA and pEGFR. This 
suggests presence of multiple cancer stem cell subpopulations in our organoids 
including but not limited to CD133 expressing, ALDH1 expressing and CD44 expressing 
populations that have widely studied in PDAC. B) DAPI stained organoids with 
autofluorescent cells. Organoids were paraffin embedded and sectioned. The slides 
were then DAPI stained to observed presence of any autofluorescent cells. 
Autofluorescent cells represent retention and expansion of another recently identifies 






















Fig. 3.6 Organoids growth in culture 
 
KC and KPC organoids were embedded in matrigel domes and seeded in 48 well plates 
After a two days in culture ten KC and KPC organoids were observed under microscope 
and images were clicked from multiple fields. The wells containing these organoids were 
then marked for the location of these organoids. For the next five days the location and 
size of these organoids were tracked/followed. At the end of five days pictures were 
clicked again for the tracked organoids. A) Microscopic image of KC and KPC pancreatic 
organoids that have been tracked over 5 days representing change in their size B) 
Quantification of change in the size of organoids from day 0 to day 5 to examine their 
growth in culture. The sizes of tracked organoids were measured by clicking their picture 
and measuring each organoid using the Moticon Software. Size change of the organoids 
from day 0 to day 5 was then calculated. KPC organoids grew at a higher rate in culture 









Fig. 3.7 Growth inhibition tracking in organoids 
KPC organoids were embedded in matrigel domes and seeded in 48 well plates in two 
groups “control” and “Afatinib” (A small molecule pan-EGFR inhibitor approved from 
NSCLC). After two days in culture both groups of organoids were observed under 
microscope and images were clicked. The wells containing these organoids were then 
marked for the location of these organoids. Afatinib was added at a concentration of 
0.1µM in group named “Afatinib” and control group was given equal microliters of PBS. 
For the next five days the location and size of these organoids were tracked/followed. 
Media was changed on day 2 and 4 for both groups with re-administration of Afatinib and 
PBS. At the end of five days pictures were clicked again for the tracked organoids. A) 
Microscopic image of pancreatic organoids for day 0 and day 5 in the two groups 
(Untreated “control”, Drug-Treated” Afatinib”). B) Quantification of change in the size of 
ten organoids in control and drug-treated group from day 0 to day 5. The sizes of tracked 
organoids were measured by clicking their picture and measuring each organoid using 
the Moticon Software. The average size in the group is written in red over each bar. 
Evaluation of % size change in organoids upon drug treatment to evaluate therapy 
response. Therapy response was evaluated by comparing change in organoids over 5 
days in the two groups. Control organoids showed in average 7% increase in their size 
(area). Drug-treated organoids decreased in size by 56% suggesting successful 



























CHAPTER 4: PANCREATIC CANCER STEM CELL TARGETING: AFATINIB 















Improving disease-free survival and a patient’s quality of life is the comprehensive goal 
of research against PC. Although several therapies have been tried, none has 
significantly improved patient outcomes. The present therapeutic options for advanced 
metastatic PC primarily include gemcitabine and its combination with erlotinib or nab-
paclitaxel or FOLFIRINOX [7]. Despite all the available therapies and surgical 
interventions, the average five-year survival rate for PDAC patients is merely 8% [7]. The 
primary cause of PC mortality is metastasis. Approximately 53% of patients upon 
diagnosis present with an advanced metastatic stage of the disease [7]. Furthermore, 
emerging evidence suggests that PC is metastatic even at its conception, which makes 
targeting this aggressive metastatic cancer a challenging task [5]. One of the major 
factors contributing to metastasis is mobilization of CSCs [185, 186] a small 
subpopulation of cells in the tumor also referred to as side population (SP) which has 
been shown to be vital for PC metastasis and drug-resistance [2, 187]. These cells are 
also responsible for drug resistance and disease relapse in PC and other types of 
cancers [2]. Conventional chemotherapeutic drugs act on differentiated tumor cells but 
fail to target the CSC population. It is now clear that the success of new PC therapies in 
achieving durable remissions will depend on targeting CSCs; therefore, understanding 
mechanisms for targeting PCSCs is critical. 
The EGFR family of proteins are involved in the initiation and progression of PC, with 
EGFR mutations being essential for the initiation process [188]. Many ongoing clinical 
trials are using inhibitors against EGFR family of proteins for therapy against cancers. 
The USFDA recently approved one such inhibitor erlotinib in combination with 
gemcitabine for the treatment of advanced PC; however, later this treatment caused 
dose-limiting toxicity and failed to control the compensatory changes in the 
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phosphorylation of HER3, resulting in resistance against erlotinib [189, 190]. Afatinib is a 
third-generation EGFR family inhibitor and has been shown to be superior in inhibiting 
PC cell lines when compared to erlotinib [190]. It is an FDA-approved drug for non-small 
cell lung carcinoma and is being investigated for several other cancers [191, 192].It is a 
pan-EGFR inhibitor (targeting all EGFR family proteins) and is presently being 
investigated as a single agent and in combination with other chemotherapeutic drugs in 
49 clinical trials; however, few studies have examined its effects on CSC populations in 
different cancers [193]. Our previous study has shown that afatinib can be used to inhibit 
EGFR proteins in vitro and reduce colony formation and invasion of PDAC cell lines 
[194]. 
Here we tested the potential of afatinib in specific targeting of the PCSCs along with 
differentiated cancer cells. We identified that afatinib inhibits a novel 
EGFR/ERK/FOXA2/SOX9 axis and abrogates PCSC. Through inhibition of PCSC the 













4.2.1 High self-renewal marker expression in Gemcitabine treated and high-grade 
pancreatic cancer. 
The present standard of care for pancreatic cancer patients is either neoadjuvant 
chemotherapy or chemotherapy depending on the spread and grade of the disease. 
Cancer stem cells have been shown to remain intact even upon standard 
chemotherapeutic treatments in pancreatic cancer [195]. Additionally, some recent 
studies have suggested CSC enrichment due to chemotherapeutic drugs [196, 197]. 
With an objective to examine the presence of CSC population in PDAC patients, we 
immunofluorescent stained PDAC tissue microarray for the presence of CSC and self-
renewal markers like SOX9, CD44, ESA and CD133 (Fig. 4.1A). We observed enhanced 
expression of these markers in PDAC tissues compared to normal pancreatic tissue. 
Upon segregating tissue samples according to patient grade, we found an increase in 
these markers as the grade and severity of PDAC increases (Fig. 4.1A,B). There was a 
significant increase in expression of these markers from normal pancreatic tissue to 
PDAC stage II grade 2 malignant tissue and finally to PDAC stage III grade 3 malignant 
tumors. Amongst these markers, SOX9 is known to be a master regulator for several 
stem cell genes in the pancreas as well as a valuable marker for the ductal lineage of 
pancreatic cancer cells [198, 199]. To examine how chemotherapeutic treatments, affect 
PCSCs we immunohistochemically stained human PDAC tissue microarray for SOX9 
expression. The stained slides were scored with the help of a pathologist. A subset of 
PDAC tumors with a history of chemotherapeutic treatment were found to express a 
significantly higher amount of SOX9 compared to patient samples with no history of 
chemotherapy (Fig. 4.1 C). Although when the collective of all samples were compared 
the difference in SOX9 expression was not significant which can be attributed to 
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extensive intertumoral heterogeneity that exists in PDAC. High expression of CSC 
markers in PDAC samples and patient samples with a history of chemotherapeutic 
treatments suggests the role of PCSCs in disease aggressiveness and a probable 
enrichment upon chemotherapy. 
 
4.2.2. Development and characterization of murine PC organoids 
Pancreatic tumor organoids developed from neoplastic pancreatic duct cells were 
previously shown to retain the same attributes as the pancreatic ductal adenocarcinoma 
(PDA) stage [137]. Therefore, to examine the treatment efficacy of afatinib and 
gemcitabine on PC, we generated organoids from pancreatic tumor tissues of KC and 
KPC mouse. (Fig. 4.2A). Once developed, they grew as single-cell-layered ductal 
structures in vitro and developed more complex structures as the days progressed (Fig. 
4.2B, Fig. 4.2C). 3-D tumor organoids were used since they are more physiologically 
relevant than traditional monolayer cultures to test therapy response [93]. 
Afatinib and gemcitabine inhibit the growth of tumor organoids derived from KC, KPC 
mice, and human PC tumors. 
EGFR family of proteins are implicated in multiple cancers including PC [200]. In PC, the 
presence of EGFR in serum has been shown to be correlated with poor prognosis [201], 
and inhibition of EGFR via erlotinib has shown survival benefits for PC patients [202]. 
Once developed, KC and KPC organoids and human PC tumor (Supp. Fig. 1A and Fig. 
1A, B and C) were treated with afatinib alone and in combination with gemcitabine. 
Results showed that KC and KPC control organoids left untreated grew in size by 45% 
and 60% respectively (Supp. Fig. 1B, C and Fig.4.2D, E,) which we attributed to their 
normal growth. Upon afatinib treatment, KC and KPC organoids decreased in size by 
25% and 16% (Supp. Fig. 1B. C and Fig. 4.2D, E); we also observed an increase in the 
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size of KC and KPC organoids by over 50% on treatment with gemcitabine (Supp. Fig. 
1C, D). Since the growth of these organoids has been linked to their ability to maintain 
progenitor cells or stem cells [203], we presume that the increase in the size of the 
organoids is due to enrichment of CSCs upon gemcitabine treatment. Our results 
showed combination treatment with afatinib and gemcitabine decreased KC organoid 
size by 57% (Supp. Fig. 1B, C), suggesting a potential synergistic effect of the 
combination in inhibiting PDAC. 
Interestingly, the concentration of afatinib (0.1 μm) employed in KC organoids was not 
sufficient to restrict the growth of KPC organoids (Supp. Fig. 1F). We found that an 
increased concentration of afatinib (0.5 μm) with gemcitabine (1 μm) inhibited KPC 
organoid growth and size by over 50% in comparison to untreated control, which grew in 
size and complexity. In both KC and KPC organoids, the untreated KPC control 
organoids evolved from single-cell-layered ductal structures to more complex cribriform 
structures, whereas afatinib restricted this growth (Fig. 4.2E, and Supp. Fig. 1C). The 
combination also visibly eradicated complex organoid structures as revealed by H&E-
stained sections (Fig. 4.2E, and Supp. Fig. 1C), which suggests the therapy could 
reduce the aggressiveness of PC. Over 40% of organoids remaining after seven days of 
consecutive combination treatment in both KC and KPC organoids were broken, showed 
no structural complexity or were eradicated or dead (Supp. Fig. 1D, E). 
Further, we developed human pancreatic tumor organoids (Fig. 4.2C) to test the efficacy 
of afatinib and gemcitabine and their combination. Treatment with afatinib significantly 
reduced the size of human pancreatic tumor organoids compared to control, whereas 
the gemcitabine-treated organoids did not show any significant variation in size (Fig. 
4.2F, G). However, the combination of afatinib and gemcitabine treatment significantly 
reduced pancreatic tumor organoids size (Fig. 4.2F, G). Overall, these results suggest 
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that afatinib alone and in combination with gemcitabine can decrease tumorigenesis and 
growth in PC. 
4.2.3. Combination of afatinib and gemcitabine significantly inhibits PC cell 
growth and in vivo primary tumor and metastasis 
To further determine the effects of afatinib and gemcitabine combination treatment on 
PC cell lines, SW1990 and Capan1 cells were treated with different concentrations of 
afatinib and gemcitabine for 24 h, and the IC50 value was calculated using MTT analysis 
(Supp. Fig. 2A). To evaluate the inhibitory effect of afatinib and gemcitabine on the 
EGFR family of proteins, SW1990 and Capan1 cells were treated with afatinib and 
gemcitabine alone and in combination for 48 h. We found that treatment with afatinib 
alone and in combination with gemcitabine effectively downregulated the 
phosphorylation of EGFR, Her2, and Her3, with no change to their total protein 
expression (Fig. 4.3A). However, treatment with gemcitabine alone leads to increased 
phosphorylation of EGFR family proteins when compared to afatinib treatments. 
Furthermore, we tested the combination therapy in vivo in xenograft nude mouse model 
of PC. For this, athymic nude mice were orthotopically injected with luciferase-labeled 
Capan1 cells into the head of the pancreas, and then divided into four groups (7 mice 
per group): control (PBS), afatinib (orally), gemcitabine (intraperitoneal) and the 
combination of both (Fig. 4.3B.) Afatinib treatment reduced the primary tumor burden by 
over 1.8-fold (Fig. 4.3C, D) and reduced the number of metastasis spots per organ 
(Supp. Fig. 2B); afatinib also decreased the metastatic incidence to the liver by 16-fold, 
mesenteric lymph nodes and intestine by 8-fold and diaphragm and stomach by 4-fold 
when compared to control (Fig. 4.3E, F). A combination of afatinib and gemcitabine 
reduced the primary tumor by 2.4-fold compared to 1.5-fold by gemcitabine alone (Fig. 
4.3C, D). The combination also decreased the incidences of metastases by 16-, 4-, 32-, 
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8- and 4-fold in the liver, mesenteric lymph node, diaphragm, and stomach, respectively 
(Fig. 4.3E, F). Taken together, these results suggest that afatinib treatment in 
combination with gemcitabine can improve the anti-tumor effect of gemcitabine in PC. 
4.2.4. Afatinib decreases the SP/CSC population and tumorsphere formation in PC 
cells. 
The decrease in tumor weight and metastasis in the xenograft mouse model encouraged 
us to analyze the PCSC population because of its association with metastasis , poor 
prognosis, and drug resistance in PC [204] . Hoechst-based FACS analysis was used to 
analyze and isolate the CSC population as described in Materials and Methods (Fig. 
4.4A). We next measured the drug sensitivity (IC50 values) of PCSC cells for 
determining an effective drug dosage (Supp. Fig. 2A). SP cells were found to be more 
sensitive to afatinib: 46.93% in Capan1 and 56.7% in SW1990 in comparison to their 
parental populations. We also report that the SP fraction is more resistant to gemcitabine 
(27.45% in Capan1 and 26.4% in SW1990 of parental populations) when compared to 
their parental counterparts. Based on these results, we suggest that the SP fraction is 
more sensitive to afatinib and resistant toward gemcitabine (Supp. Fig. 2A). To further 
evaluate the effect of afatinib on CSC/SP populations, PC cells were subjected to 
afatinib, gemcitabine and the combination treatment of both the drugs for 48 h and then 
stained with Hoechst 33342 (a fluorescent DNA-binding dye) to analyze the CSC/SP 
cells by FACS analysis [88, 205]. Afatinib and combination treatment significantly 
decreased CSC/SP cells when compared to control cells; however, gemcitabine 
treatment increased the proportion of CSC/SP cells (Fig. 4.4B, C, D, E). This result 
suggests that afatinib is effectively inhibiting the CSC population while gemcitabine is 
enriching it. To further validate the effect of afatinib on PCSCs, we performed 
immunofluorescence analysis on SW1990 and Capan1 cells and found that treatment 
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with afatinib inhibits the expression of CSC markers such as ESA, ALDH1, OCT4, and 
SOX9 along with pEGFR (Supp. Fig. 3A and B) in PC cells. We also examined the effect 
of afatinib on self-renewal and tumorigenic potential in CSCs using tumorsphere assay 
on the isolated SP. Treatment with afatinib for 48 h significantly reduced the number of 
tumor spheres (Fig. 4.4F, G), which further indicates that afatinib affects tumorigenic and 
self-renewal properties of SP cells. 
4.2.5. Treatment of afatinib significantly decreases the CSC markers in tumor 
organoids and in pancreatic xenograft tumors 
Our data demonstrated that afatinib acts on PCSCs and reduces their stemness and has 
a pronounced anti-cancer effect when given in combination with gemcitabine. Therefore, 
we next asked whether afatinib can downregulate the CSC markers in KPC organoids or 
in the xenograft tumors. KPC tumor organoids were sectioned and immunostained for 
CSC markers such as CD44v6, ALDH1, CD133, ABCG2, OCT4, SOX2, and ESA, along 
with pEGFR. Confocal imaging of KPC organoids shows afatinib treatment drastically 
reduced CD44v6, ALDH1, CD133, ABCG2, OCT4, SOX2, ESA and pEGFR, which were 
further decreased by treatment with afatinib and gemcitabine combined compared to the 
untreated control and gemcitabine-treated groups (Fig. 4.5 A, B and Supp. Fig. 4A). To 
determine whether afatinib might also affect the CSC markers in vivo, we fluorescently 
stained the pancreatic tumors resected from the xenograft experiment for CSC markers, 
i.e., CD133, CD44v6 ESA and pEGFR (Fig. 4.5C, D). Afatinib treatment alone and in 
combination with gemcitabine decreased CSC markers in primary tumors, suggesting 
that afatinib is inhibiting PCSC stemness by downregulating CSC markers. Expression 
of CD44v6 and CD133 has been shown to be critical drivers of PC metastasis [206-209], 
and ESA is a well-known marker for PCSCs [210] Reduction in these markers further 
demonstrates the efficacy of afatinib against PCSC. Interestingly, we also observed an 
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increase in the same markers with gemcitabine treatment, which corroborated our 
previous data suggesting gemcitabine enriches CSCs (Fig. 4.5 C, D). Since we saw a 
decrease in primary tumor weight, we wanted to analyze the correlation of primary tumor 
weight with metastatic incidence. Primary tumor weight correlated poorly with metastatic 
incidence (Supp. Fig. 2C). These results suggest that a decrease in CSC markers by 
afatinib may have led to a decrease in metastatic incidence. 
4.2.6. Afatinib abrogates CSC markers and oncogenic signaling in CSCs 
We next attempted to further explore the action of afatinib on self-renewal and CSC 
markers in PCSCs. As expected, afatinib alone and in combination with gemcitabine 
decreased self-renewal and CSC markers ALDH1, CD44, SOX2, SOX9, ESA, and 
ABCG2 and inhibited activation of oncogenic proteins such as ERK and FAK (Fig. 4.6A). 
To further validate our observation, we first isolated the SP and the NSP cells from 
SW1990 as described above, and characterized their CSC markers; SP-SW1990 
expressed higher amounts of SOX2, PAF1/PD2, ESA, ALDH1, SOX9, CD44v6, ESA 
and SHH than its NSP counterparts (Fig. 4.6B). The SP-SW1990 cells were then 
subjected to IC25 and IC50 concentrations of afatinib, which decreased expression of 
CD44v6, ESA, SOX9 and ALDH1 along with pEGFR and pHer2 (Fig. 4.6C). Next, we 
performed immunofluorescence analysis on the SP cells (isolated from SW1990 and 
Capan1) and observed downregulation of ALDH1, ESA, SOX9 and OCT4 upon afatinib 
treatment (Fig. 4.6 D, E, F, G). These results suggest that afatinib inhibits PCSC by 
down-regulating molecules vital for CSC maintenance and self-renewal and hence 
inhibiting stemness in CSCs. 
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4.2.7. Afatinib decreases CSC populations via ERK/FOXA2/SOX9 signaling in 
PCSCs. 
To delineate the mechanism of action of afatinib, we performed a PCR array comparing 
vital transcription factors and CSC markers in SW1990 cells (Fig. 4.7A). SW1990 cells 
were treated with afatinib (IC50) for 4 days, followed by RNA isolation and PCR array 
analysis. Afatinib treatment led to a greater than 2-fold decrease in 23 transcription 
factors (ABCB5, ALCAM, BMP7, CD38, CD44, DACH1, DLL4, FOXA2, ITGA2, JAG1, 
KLF4, MERTK, NOS2, PECAM1, PLAT, PLAUR, PTPRC, SNAI1, TAZ, TWIST2, ACTB, 
B2M and HGDC) important for CSCs (Fig. 4.7A). These results were further validated by 
qPCR and these genes were found to be downregulated upon four days of treatment 
(Supp. Fig. 5C). We focused on FOXA2 because of its importance in promoting self-
renewal of pancreatic progenitor cells [211, 212]. FOXA2 is involved in regulation of 
SOX9 expression, which is another self-renewal marker for PCSC[212]. We performed 
qRTPCR analysis for FOXA2 and SOX9, which showed a decrease in mRNA levels 
upon afatinib treatment on SP-SW1990 (Fig. 4.7B) suggesting a probable mechanism of 
action. A scanning of the SOX9 promoter region for binding motifs for FOXA2 revealed 
eight possible binding sites (Supp. Fig.5A) are the further corroborating possibility of 
FOXA2 regulating SOX9. It has been reported previously that the phosphorylated form 
of ERK regulates FOXA2 transcription, and hence we examined pERK levels. As 
expected, afatinib treatment decreased pERK levels in PC cell line as well as in the 
isolated SP/CSC population, suggesting that afatinib inhibits PCSCs by inhibiting 
EGFR/ERK /FOXA2/SOX9 signaling (Fig. 4.7D, E). 
To confirm this mechanism, we transiently knocked down EGFR (Fig. 4.7C) in isolated 
SP/CSCs. Results showed that EGFR knockdown led to inhibition of pERK, SOX9 and 
FOXA2 expression along with multiple other CSC markers such as OCT4, NANOG, and 
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DCAMLK1 (Fig. 4.7C), confirming that the decrease in CSC markers and the 
downstream signaling was due to EGFR inhibition. To further confirm the proposed 
mechanism, we used two independent siRNAs to downregulate FOXA2 mRNA, which 
led to a decrease in SOX9 expression, further corroborating the signaling axis 
(pEGFR/pERK/FOXA2/SOX9) that is modulated by afatinib. To determine if afatinib 
engages the same mechanism in organoids and xenograft tissues, KPC organoids and 
xenograft sections were stained with pERK, FOXA2, and SOX9. The results showed that 
afatinib decreased expression of these markers (Fig. 4.7G, Supp. Fig 4B, C, and Supp. 
Fig. 5B, C, D). Altogether, our data provide a novel mechanism of action by which 





PC is a devastating disease with an abysmal prognosis [7, 213]. Current 
treatment options that provide a survival advantage for advanced metastatic PDAC 
include irinotecan liposome injection, gemcitabine, erlotinib, FOLFIRINOX, nab-
paclitaxel, and combinations of these drugs. Such available therapies offer a 5-year 
survival rate of merely 8% and an average overall survival benefit of 5.6 months to 11 
months [214]. Aggressive and early metastasis is the chief cause of mortalities in PDAC, 
and present evidence supports that PDAC may start disseminating as early as its 
inception, accounting for the dismal prognosis [5, 193, 210, 215]. The cells that likely 
initiate early metastasis are CSCs, which have the potential to seed tumors, promote 
metastasis and provide drug resistance [193, 210, 215].Targeting CSCs may provide an 
opportunity to impede tumor growth and metastasis in PDAC; however, currently used 
therapies fail to inhibit these cells [7, 193, 216]. We report an increase in expression of 
CSC markers in PDAC as the grade and severity of PDAC increases which is potentially 
unaffected by chemotherapy. These results highlight the importance of developing 
targeted therapy directed towards the CSC population in PDAC. Our study outlines a 
strategy to effectively impede CSCs in PDAC by inhibiting their maintenance and 
stemness properties. 
As a strategy to target pancreatic CSCs, we tested combination therapy of pan-
EGFR inhibitor, afatinib with first-line therapeutic drug gemcitabine. PDAC is known to 
overexpress EGFR family members HER1 (40-70%) and HER2 (22%) [194], which are 
vital for the self-renewal and maintenance of CSCs in PC [216]. Inhibition of EGFR 
family proteins has been reported to downregulate tumor growth and metastasis in 
multiple studies of PDAC. Furthermore, afatinib inhibits all four EGFR family members 
by binding to their ATP binding domain and inactivating them [217]. Although afatinib is 
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an FDA-approved drug for non-small cell lung carcinoma, emerging evidence suggests 
its role as a potent inhibitor of multiple tumor types [190, 191, 217]. In this study, we 
illustrated that inhibition of EGFR family of proteins using afatinib significantly reduced 
the stemness properties of pancreatic CSCs and provided antitumor activity against PC 
that was enhanced with gemcitabine treatment. Similarly, several other studies have 
reported that EGFR family inhibition suppresses CSCs in brain, lung and breast cancers, 
amongst others [218-220]. In addition, our study has shown that pan-EGFR inhibition 
downregulates pancreatic tumor growth in xenograft mouse models. 
To test the effect of afatinib in PDAC models, we developed 3-D tumor organoids 
from KC and KPC autochthonous mouse tumors, which show clear progression 
structures similar to PDAC progression. Emerging studies have substantiated the use of 
tumor organoids for therapeutic response studies because of their high physiological 
relevance [93] to the tumor. Tumor organoids recapitulate tumor architecture and biology 
in vitro [137] and maintain a robust population of CSCs, making them ideal for our study. 
Treatment with afatinib alone or with gemcitabine drastically inhibited the tumor size and 
architecture in both models of tumor organoids as compared to gemcitabine alone, 
demonstrating its effectiveness in impairing tumor growth. This was in concordance with 
the reduction in tumor burden and metastatic incidence compared to gemcitabine alone 
as observed in our xenograft mouse model experiments. These results also align with 
our previous publication depicting a reduction in tumor burden upon inhibition of EGFR 
family proteins by canertinib [194]. The observed increase in tumor organoid size and 
structural complexity upon gemcitabine treatment, although not significant, may stem 
from the enrichment of pancreatic CSCs, since CSCs are resistant to gemcitabine [215]. 
Interestingly, afatinib alone and in combination with gemcitabine decreased 
distant metastatic spread suggesting afatinib could be effective in inhibiting the 
metastasis in PDAC patients. This potential is supported by various other reports of 
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metastasis being linked to the overexpression and amplification of EGFR and its other 
family members HER2, HER3 and HER4 in several primary cancers like colorectal, 
ovarian, non-small cell lung carcinoma and pancreatic cancer [221-224].CSCs are 
known to be vital for metastasis in multiple cancers including PC. Thus, we decided to 
analyze the effect of afatinib on the CSC population. Our data revealed that afatinib 
significantly reduces the SP/CSC population in PDAC cell lines and inhibits their self-
renewal and tumorigenic potential. Furthermore, our immunofluorescence staining 
results showed that afatinib treatment downregulated the expression of pEGFR and 
CSC markers such as CD44v6, ALDH1, ESA, and CD133 in PC organoids and 
xenograft tumor tissues.   
In our study, we delineated a novel mechanism by which afatinib selectively 
inhibits CSCs in PC. Afatinib treatment reduced several CSC markers along with 
oncogenic signaling molecules like ERK and FAK. Additionally, we found afatinib 
downregulated 22 vital transcription factors and CSC markers by more than two-fold 
compared to control. Among them were several genes essential for PCSC maintenance 
like KLF4, CD44, SNAIL1, TWIST2, FOXA2, and TAZ. FOXA2 caught our attention 
because of its role in stem cell self-renewal [225]. It is also vital for lineage specification 
in the pancreatic formation, and its expression is essential for pancreatic progenitor 
cells. FOXA2 is also known to regulate SOX9 [212] Both SOX9 and FOXA2 were 
downregulated by afatinib treatment, and availability of FOXA2 binding motifs in SOX9 
proximal region suggested a probable mode of action. SOX9,is known to be vital for 
CSC self-renewal and is a master regulator for several stem cell markers, is also 
regulated by pERK [226] which is a downstream molecule of EGFR. This led us to 
hypothesize that afatinib is targeting the EGFR/ERK/FOXA2/SOX9 axis to inhibit PCSCs 
and their stemness properties. Our hypothesis was confirmed when knockdown of 
EGFR decreased expression of FOXA2 and SOX9 and knockdown of FOXA2 decreased 
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expression of SOX9. To further verify the mechanism of action, we stained afatinib-
treated tissue and organoid sections with fluorescent antibodies against pERK, SOX9, 
and FOXA2, and observed decreased expression of these stemness molecules. Overall, 
these results affirm that afatinib inhibits CSC maintenance and proliferation via 
EGFR/ERK/FOXA2/SOX9 inhibition in PC, thereby decreasing PC growth and 
metastasis 
In conclusion, afatinib treatment alone decreased the CSC/SP fraction in PC 
models by altering their self-renewal/tumorigenic potential. Afatinib, unlike gemcitabine, 
reduced tumor organoid size and architecture and inhibited CSC markers within these 
organoids. Furthermore, combination therapy with afatinib and gemcitabine effectively 
reduced tumor burden and metastatic incidence in a xenograft model of PC. Our 
mechanistic studies indicate that afatinib acts on PCSC by inhibiting EGFR/ERK/FOXA2 
to target SOX9. Altogether, we have shown that afatinib inhibits stemness properties in 
pancreatic CSCs and in combination with gemcitabine may provide a potent therapy 
against pancreatic CSCs; thus, this novel combination therapy may improve clinical 




4.4. Figures and Legends 
Fig.4.1. High self-renewal marker expression in Gemcitabine treated and high-
grade pancreatic cancer. 
A) Representative immunofluorescence image of Human tissue microarray with 
pancreatic cancer and normal pancreatic cores stained with SOX9, CD44, ESA and 
CD133, CSC and self-renewal markers (PDAC stage II grade 2 malignant, PDAC stage 
III grade 3 malignant, normal pancreatic tissue). B) Quantitative analysis of CSC marker 
expression in stained tissue microarray cores. Mean fluorescent intensities for Red, 
Green and Blue stains was noted for each picture. Red and green staining was then 
normalized by blue stain to get normalized mean fluorescent intensities. C) 
Quantification of IHC scoring for expression of SOX9 in patient samples treated with 
chemotherapy versus no chemotherapy depicting an increase in its expression upon 
chemotherapeutic treatment. A human tissue microarray with information about the 
primary and secondary treatments provided to the patients was stained 
immunohistochemically for expression of SOX9. The array was then scored for SOX9 
staining with the help of a pathologist, for comparative analysis cores were divided into 
two groups; Chemotherapy (the samples that had a history of chemotherapy with 
gemcitabine of 5FU) and No Chemotherapy (the samples that had no history of 
chemotherapy). A subset of 7 cores/samples treated with chemotherapy had significantly 
high expression of SOX9 compared to average staining in no chemo group. These 
sections were immunohistochemically scored for SOX9 expression.( P<0.05: *, P<0.001: 

















Fig.4.2. Effects of afatinib on the development of pancreatic cancer (PC) 
organoids.  
A) Experimental scheme is showing the development of organoids and the treatment 
strategy. B) Microscopic images of hematoxylin and eosin (H&E)-stained KPC mouse 
PC organoids at days 2, 3 and 5. C) Microscopic images of H&E-stained human PC 
organoids at days 2, 3 and 5. 
Human PDAC organoids were embedded in matrigel domes and seeded in 48 well 
plates in groups as per the scheme in “4.2A”. After two days in culture all four groups of 
organoids were observed under microscope and images were clicked. The wells 
containing these organoids were then marked for the location of these organoids. Drugs 
were added at concentrations of 0.5µM Afatinib and 0.50.5µM Gemcitabine and control 
group was given equal microliters of PBS. For the next five days the location and size of 
these organoids were tracked/followed. Media was changed on day 2 and 4 for both 
groups with re-administration of drugs and PBS. At the end of five days pictures were 
clicked again for the tracked organoids. The sizes of tracked organoids were measured 
by clicking their picture and measuring each organoid using the Moticon Software. 
Therapy response was evaluated by comparing change in organoids over 5 days in the 
groups. D) Quantitative analysis of the average size change in control and treated KPC 
mouse organoid groups (Control, Afatinib, Gemcitabine, Afatinib, and Gemcitabine 
combination treatments) over 5 days of treatment. E) Microscopic images of KPC PC 
organoids before and after treatment for 5 days, and H&E-stained sections at the end of 
the treatment. F) Quantitative analysis of the average size change in control and treated 
human PC organoid groups (Afatinib, Gemcitabine, Afatinib, and Gemcitabine 
combination treatments) over 5 days of treatment. G) Microscopic images of human PC 











Fig. 4.3. Afatinib and gemcitabine combination treatment inhibits pancreatic tumor 
growth and metastasis in an in vivo xenograft mouse model.  
A) Effect of treatments (Afatinib, Gemcitabine alone and Afatinib with Gemcitabine 
combination treatment) on the EGFR family of proteins in PC cell lines SW1990 and 
CAPAN1. Cell lines were treated at IC50 concentrations. B) Study design for in vivo 
mouse experiments. C) Statistical analysis of murine primary tumor weights upon study 
completion. Upon euthanasia mice tumors were resected and weighed. D) Diffused 
luminescent imaging tomography (DLIT) images of mice after 4 weeks of treatment 
before resection. E) Metastasis incidence in mice after 4 weeks of treatment. Upon 
euthanization internal organs of the mice were harvested and metastatic spots were 
counted on the organs to calculate metastatic incidence F) Microscopic images of H&E-








Fig.4.4. Afatinib inhibits cancer stem cell (CSC) counts and stemness.  
A). Experimental design for experiments in the CSC population. B-C). PC cells were 
seeded and treated with IC50 concentrations of Afatinib, Gemcitabine, a combination of 
Afatinib and gemcitabine. Following 48 hours of treatment cells were subjected to FACS 
analysis for side population to identify low Hoechst staining CSC population. Percentage 
of side population (SP) cells in PC cell lines (B. SW1990 and C. Capan1) after 48 hours 
of treatment. D-E). FACS analysis showing SP fraction in control and treatment groups 
(Afatinib, Gemcitabine and Afatinib and Gemcitabine combination treatments) after 48 
hours (D. SW1990 and E. Capan1). F-G). Isolated SP/CSC population was seeded in 
low attachment pates in two groups (Control, Afatinib). IC50 concentration of Afatinib 
was added to Afatinib after 24 hours of cell seeding. Effects of afatinib on isolated CSC 
populations in tumor sphere assays; tumor sphere counts, and representative 








Fig.4.5. Afatinib and gemcitabine combination inhibits pancreatic CSCs (PCSCs) 
in KPC mouse tumor organoids and primary mouse tumors.  
A. Immunofluorescence images of CSC markers and pEGFR in KPC mouse organoids 
after treatment (Control, Afatinib, Gemcitabine and Afatinib with Gemcitabine 
combination treatments), scale bars=10 μM, zoomed scale bars=5 μM. B. Quantitative 
analysis of CSC marker expression in stained organoids from panel A. C. Immuno-
stained images of CSC markers and pEGFR in mouse primary tumors after treatment 
(Control, Afatinib, Gemcitabine, and Afatinib and Gemcitabine combination treatments), 
scale bars=10 μM, zoomed scale bars=5 μM. D. Quantitative analysis of CSC marker 










Fig.4.6. Afatinib inhibits CSC stemness by downregulating multiple CSC markers 
in PC cells.  
A. Treatment with afatinib downregulates CSC markers and oncogenic markers in PC 
cells. SW1990 cells were seeded for 24 h and subjected to drug treatment in 4 groups 
(Control, Afatinib, Gemcitabine and Afatinib, and Gemcitabine combination treatments) 
at IC50 concentrations for 48 hours, followed by western blot analysis. B. SP cells 
isolated by Hoechst-based FACS express higher amounts of CSC and self-renewal 
markers than non-side population (NSP) cells. C. SP-SW1990 cells were treated with 
IC20 and IC50 concentrations of afatinib, which downregulates the EGFR family of 
proteins and CSC and self-renewal markers. D-E. Immunofluorescence analysis 
showing that afatinib represses CSC and self-renewal markers (D. SP-SW1990 and E. 
SP-Capan1), scale bars=20 μM. F-G. Quantitative analysis of panels D. and E. (F. SP-







Fig.4.7. Afatinib decreases the CSC population via EGFR/ERK/FOXA2/SOX9 
signaling in PCSCs.  
A. PCR array for CSC and self-renewal markers in SP/CSC cells (SP-SW1990) after 4 
days of treatment in the culture at IC50 concentrations. B. Afatinib treatment leads to 
downregulation of FOXA2 and SOX9 RNA and FOXA2 protein. C. Transient repression 
of EGFR by independent siRNAs in SP-SW1990 cells downregulates pERK, FOXA2, 
SOX9, DCAMLK1, NANOG, and OCT4. D. Protein expression of pERK, FOXA2, and 
SOX9 in SW1990 cells upon treatment with afatinib and gemcitabine alone and in 
combination. E. Downregulation of pERK, FOXA2, and SOX9 at IC20 and IC50 
concentrations of afatinib in the SP/CSC population of SW1990. F. Downregulation of 
SOX9 upon transient knockdown of FOXA2 in the SP/CSC population of SW1990. G. 
Immunofluorescence images of afatinib-treated KPC tumor organoids and mouse 
primary tumors depicting the reduction of FOXA2 and SOX9. H. Schematic model of the 











Supplementary Figure 1. 
Effects of afatinib on KC and KPC organoids. A. Microscopic images of H&E-stained PC 
organoids from KC mice. B. Microscopic images of KC mouse organoids before and 5 
days after treatment, and H&E-stained sections at the end of the treatment. C. 
Quantitative analysis of the average size change in control and treated KC PC organoid 
groups (Afatinib, Gemcitabine, and Afatinib and Gemcitabine combination treatments) 
over 5 days of treatment. D-E. Percentage of organoids estimated to be dead based on 
microscopic analysis of the morphology. D. KC tumor organoids. E. KPC tumor 
organoids. F. Quantitative analysis of the average size change in control and treated 
KPC mouse organoid groups (Afatinib, Gemcitabine and Afatinib and Gemcitabine 







Supplementary Figure 2. 
A). To judge the sensitivity of PC cells (SW1990 and Capan1) to gemcitabine and 
afatinib, the IC50s for both drugs were calculated for PC cell lines and their respective 
SP/CSC isolated line. B) Mice were orthotopically injected with Capan1 cells and treated 
in 4 groups (control, Afatinib, gemcitabine, a combination of gemcitabine and Afatinib) 
after 4 weeks of implantation. After 3 weeks of treatment, mice were euthanized, and 
internal organs of the mice were harvested, a number of metastatic spots were counted 
on each organ. Histogram depicting the number of metastatic spots per organ. C) Dot 
plot depicting the correlation between tumor size and metastasis. Metastasis incidence 
and primary tumor weights were calculated for the mice and to evaluate the impact of 
tumor size on metastasis the correlation between the two was calculated. The figure 
depicts a lack of correlation between primary tumor size and metastasis incidence 
suggesting the decrease in metastasis could have been due to the therapy and not the 







Supplementary Figure 3. 
Immunofluorescence images of SW1990 and Capan1 cells, showing downregulation of 







Supplementary Figure 4. 
A. Downregulation of other CSC and self-renewal markers upon treatment (Control, 
Afatinib, Gemcitabine, and Afatinib and Gemcitabine combination treatments) in KPC 
organoids, Scale bars=10 μM. B. Immunofluorescence images of KPC organoids treated 
with afatinib, depicting a reduction in pERK, FOXA2, and SOX9 along with CSC marker 
DCAMLK1, scale bars=10 μM. C. Quantitative analysis of CSC and self-renewal 







Supplementary Figure 5.  
A. FOXA2 binding motifs for SOX9 promoter region. B.Immunofluorescence images of 
KPC mouse primary tumors after 4 weeks of afatinib treatment, depicting a reduction in 
pERK, FOXA2, and SOX9 along with CSC marker DCAMLK1, scale bars=10 μM. C. 
Quantitative analysis of panel B. D. qPCR analysis of CSC and self-renewal markers 






































5.1.1 Organoids for preclinical research 
Three-dimensional (3D) cultures use the inherent nature of cells to self-organize 
and generate structures that can be programmed to represent an organ or a pathology. 
Organoid cultures are the 3D cultivation of source tissue (ranging from cells to tissue 
fragments) in a support matrix and specialized media that nearly resembles the 
physiological environment. Depending on the source tissue, growth factors, and 
inhibitors provided, organoids can be programmed to recapitulate the biology of a 
system and progression of pathology. Organoids are genetically and phenotypically 
stable, and genetically amenable, making them very suitable tools to study tissue 
homeostasis and cancer.  
One of the goals of the dissertation was to develop in vitro three-dimensional 
models to test therapeutic response. For this, we developed pancreatic cancer 
organoids from KC (KrasG12D; Pdx1Cre), KPC ( KrasG12D; Trp53R172H/+; Pdx1Cre ) and PDAC 
patient samples. This was achieved by modifying protocol from the pioneering Hutch et 
al. publication and further standardizing it for our laboratory and experimental needs. 
Our organoids grew in culture and demonstrated a change in morphology, from being 
organized single cellular ductal structures to unorganized structures. Our tumor 
organoids mimic PDAC architecture and environment in vitro, although with a lack of 
immune environment. These could be later used as models to study PDAC and drug 
response studies. We also report the development of lung organoids and prostate 




5.1.2 Afatinib targets CSCs in PDAC  
PC is a highly lethal disease, and CSCs are major culprits for the aggressive and 
metastatic nature of this disease. Present therapies act on differentiated cancer cells 
and fail to target CSC. EGFR family of proteins is important for CSC and PC. Afatinib is 
an FDA-approved pan-EGFR inhibitor and demonstrated superiority in vitro over 
erlotinib, a currently used drug for PC. Here we used traditional monolayer cultures, 3-D 
organoid cultures and in vivo animal models to show that inhibition of EGFR family of 
proteins using afatinib attenuates PCSC by specifically targeting a novel EGFR/ ERK/ 
FOXA2/ SOX9 axis and reduces PC growth and metastasis. This study highlights the 
importance of targeting CSCs and shows the therapeutic potential of the combination of 
afatinib and gemcitabine. 
In this study, the primary goal of my dissertation was to develop a targeted 
therapy inhibiting cancer stem cells against pancreatic cancer. For which we decided to 
focus on targeting EGFR since it is vital for cancer stem cell maintenance and highly 
expressed in PC as well as pancreatic cancer stem cells. We have used Afatinib out of 
several EGFR family inhibitors. Inhibitory effects of Afatinib were revealed when a 
significant reduction in PSCS population was observed after Afatinib treatment. 
Additionally, Afatinib inhibited tumorigenic, and self-renewal potential of PCSCs and 
down-regulated several vital PCSC markers and self-renewal markers in PC cells as well 
as the PCSCs. These results suggested a targeted action of Afatinib on PCSCs, which 
are otherwise resistant to most chemotherapeutic drugs including gemcitabine. We 
demonstrated in several experiments that gemcitabine treatment, which a very widely 
used chemotherapeutic drug against PC, leads to an enrichment of PCSCs when given 
alone whereas in combination with Afatinib treatment. This was revealed when after 
gemcitabine treatment an increase in PCSC population and enhanced expression of 
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CSC markers and self -renewal markers in PC cells but not in combination treatments. 
We demonstrated that in an orthotopic mouse model of PC Afatinib treatment inhibited 
PC and metastasis, and a combination of Afatinib and gemcitabine showed a better 
inhibition when compared to both the drugs alone. We could successfully achieve our 
first objective and inhibit PDAC and target PCSCs.  
CSCs are known to be major culprits for PDAC metastasis, and hence we 
expected that Afatinib treatment alone and in combination would inhibit CSC markers 
like CD133, CD44, and SOX9 in orthotopic mouse models tumor sections. Which we 
could test and demonstrate by Immunofluorescence staining of these tumor sections. 
We also tested the proposed therapy in 3-D tumor organoid model, since they are known 
to maintain a robust population of CSCs, and demonstrated a similar reduction in CSC 
markers and self-renewal markers. Our PCR Microarray analysis of CSC makers and 
self renewal markers revealed a list of 23(ABCB5, ALCAM, BMP7, CD38, CD44, 
DACH1, DLL4, FOXA2, ITGA2, JAG1, KLF4, MERTK, NOS2, PECAM1, PLAT, PLAUR, 
PTPRC, SNAI1, TAZ, TWIST2, ACTB, B2M and HGDC) makers which were down-
regulated. Amongst them was FOXA2 which is known to be regulated by and regulate 
SOX9 a master regulator for several CSC maintenance genes. FOXA2 is also regulated 
by pERK which is a downstream molecule in EGFR signaling. For further investigation, if 
this mechanism is being followed, we knocked down EGFR using 2 independent siRNAs 
and revealed a downstream downregulation of pERK, FOXA2and SOX 9 along with 
other CSC markers. We also knocked down FOXA2 in a similar fashion and observed a 
down-regulation of SOX9. We could identify a possible mechanism of action of Afatinib 
through EGFR/ERK/FOXA2/SOX9 axis. Immunofluorescent staining of tumor organoids 
treated with Afatinib and tumor sections from an orthotopic mouse model of PDAC 
showed a similar down-regulation of FOXA2 and SOX9 and hence confirmed or 
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mechanism of action in the 3D model and in vivo environments. Overall, we 
demonstrated a combination of Afatinib and gemcitabine could provide a potential 
targeted therapy for PDAC and its metastasis. My next goal is to understand how 
Afatinib and EGFR inhibition modifies the tumor microenvironment in PDAC. We are 
currently in the process of investigating the effect of Afatinib on CAFs and developing a 
3-D model to provide a more holistic picture of the therapy. 
Overall, our studies provide a targeted therapy against PCSCs using Afatinib and 
gemcitabine against PDAC and its metastasis. This study will also prove that cytotoxic 
therapies, like Gemcitabine, do not target pancreatic CSC, may be detrimental for 
patients. On the other hand, Afatinib, which has a specific action on pancreatic CSC 






Our overall objective was to generate targeted therapy against pancreatic cancer that 
inhibits cancer stem cells as well. We generated organoid cultures to facilitate drug 
response studies since 3D organoids provide a more robust platform that simulated 
disease architecture, biology and in most part heterogeneity. Since these aspects are 
vital to generating translatable therapies and are not recapitulated by traditional culture 
methods first part of this thesis holds much significance. We generated organoids from 
wildtype murine pancreas, KC, KPC mouse pancreatic cancer models and human 
patient samples for immediate use in this study and lung and prostate organoids for 
future metastatic studies. 
 In the second part of my thesis, we evaluate a combination therapy of Afatinib 
and gemcitabine against PDAC, its metastasis and cancer stem cell population in PDAC. 
We report that Afatinib downregulates stemness properties of pancreatic cancer stem 
cells by downregulating EGFR signaling through ERK. The downregulation of 
phosphorylated form of ERK decreases FOXA2 expression. Since FOXA2 and SOX9 
regulate each other’s expression, a decreased expression of FOXA2 causes a decrease 
in SOX9 which results in downregulation of several self-renewal genes and CSC 
markers. Due to the inhibitory action of Afatinib an PCSCs it cases a reduction in 
metastasis incidence as well as potentiates gemcitabine therapy. Hence, we report a 
combination therapy of Afatinib and gemcitabine can inhibit PCSCs and reduce 




5.3. Future Directions 
5.3.1 Organoids for preclinical research 
We successfully generated murine organoids from KC, KPC pancreatic tumors and 
wildtype pancreas. We also report the generation of organoids from patient pancreatic 
tumors and adjacent normal pancreatic tissue. 
Recent findings have reported preservation of histopathological features of the 
original tumors both in vivo and following xenotransplantation studies in immune-
deficient mice [227]. This suggests that in vitro drug responses can be examined in vivo 
in a more complex environment by organoid transplantation. The generated PDAC 
organoids can be transplanted in the immune deficient mouse to further validate the 
therapy response. 
A tumor organoid biobank was generated from 20 CRC patients and their 
matching normal tissue [228]. Integration of genomic and monotherapy drug response 
data revealed several therapeutically exploitable relations. One of the organoid cultures 
from the study was found to be sensitive to inhibition of WNT secretion due to the 
presence of RNF43 (WNT antagonist E3 ubiquitin ligase) [147, 229] . Several already 
known correlations between genetic mutations and drug responses were also observed 
along with differential cytotoxicity profiles with no genetic predictive marker. These 
results warrant further validation and hence highlight the need for the development of 
more biobanks. Last year a study reported the genetic characterization of organoid 
biobank from 39 PDAC patients [184]. The study revealed three distinct PDAC organoid 
subtypes based on gene expression subtypes revealing distinct WNT signaling 
dependencies. There is a need for the generation of more PDAC organoid biobanks for 
the generation of statistically significant inferences about therapy response and 
toxicology studies [230]. 
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Another recent study reported generation of PDAC Organoid lines from 17 
patients [176]. Organoids were reported to follow parental tumor histological features 
both in vitro and upon xenotransplantation although mutation analysis was not 
performed on the organoids. The study reveals incapability of generation of organoid 
from poorly differentiated to moderately differentiated PDACs suggesting a modification 
of protocol to allow more conclusive therapy response studies. The cell of origin of 
PDAC has been a controversial subject. Organoids generated so far have mostly been 
of ductal origin, generation of acinar organoids is critical to study the prospective role of 
ADM in PDAC (Acinar to ductal metaplasia). A study utilized a genetically engineered 
inducible mouse model of ADM to generate organoids that undergo ADM in vitro[231]. 
The study revealed that both acinar and ductal cells of origin require identical oncogenic 
drivers to trigger PDAC but differ in pathophysiology and marker expression. There is a 
need for developing protocols to generate acinar cell organoids from patient samples to 
allow further studies into studies of PDAC origin. 
Patient-derived organoids were generated from metastatic gastrointestinal 
cancer in a recent study and used to predict patient therapy response ([232]). Authors 
tested a compound library of drugs used either in current clinical trials or clinics. A 
positive predictive value of 88% (predicting that a particular drug works) and a negative 
predictive value of 100% (predicting that a particular drug does not work) was revealed 
in the study suggesting recapitulation of therapy responses from clinical trials. The study 
highlights the possibility of the development of personalized medicine platforms[232]. 
Studies have reported genetic modeling of cancer from normal organoids in CRC 
as well as PDAC [176, 233]. Co-culture systems have been established that allow 
expansion of hematopoietic cells in vitro with organoids. Short-term maintenance of 
intraepithelial lymphocytes has also been achieved in co-culture with intestinal organoids 
upon supplementation with interleukin-2 (IL-2), IL-7 and IL-15 (Nozaki et al. 2016). 
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Another recent study demonstrated maintenance of CD45+ lymphocytes up to 8 days in 
the air-liquid interphase organoid system [234]. These studies highlight the role of 
organoid co-culture systems for future studies. We have developed normal lung and 
prostrate organoids along with pancreatic cancer organoids. A co-culture system can be 
generated that includes normal organoids co-cultures with cancer organoids to simulate 
pre-metastatic niche priming and metastasis in PDAC.  
5.3.2. Afatinib targets CSCs in PDAC  
Our studies have convincingly demonstrated that Afatinib inhibits pancreatic cancer stem 
cells via EGFR/ERK/SOX9 axis and in a combination of gemcitabine inhibits pancreatic 
cancer and its metastasis.  
The interaction between the tumor and its microenvironment is complex, and a 
lot is still unknown about the communications between tumor cells and tumor 
microenvironment. Hypoxia and immune suppression are major hallmarks of the tumor 
microenvironment. The programmed cell death-ligand 1 (PD-L1) on tumor cells is a 
major part of the immune suppression module [235]. PD-L1 interacts with programmed 
cell death-1 (PD-1) on immune cells in the tumor microenvironment to avoid host 
immune surveillance [236]. Tumor cell or normal cell secreted cytokines can enhance 
tumor growth, increase metastasis and angiogenesis along with enabling immune 
evasion [237, 238]. Several studies have examined inhibition of PD-1/PD-L1 immune 
checkpoint signaling to target immune evasiveness of tumors. Expression of PD-L1 has 
also been proposed as a predictive marker for checkpoint inhibition therapy [239]. A 
correlation has been observed in the expression of PD-L1 in tumors with better 
prognosis with EGFR tyrosine kinase inhibitors in NSCLCs ([240]). Better EGFR TKI 
treatment outcome has been observed in EGFR mutant NCLCs patients, and EGFR 
mutation status is positively associated with high PDL1 expression [241, 242]. Enhanced 
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infiltrations by TILs (tumor-infiltrating lymphocytes) is associated with decreased 
metastatic recurrence in HER2-positive breast cancer treated with the anti-HER2 
monoclonal antibody, trastuzumab [243]. These studies suggest an association between 
EGFR/HER2 status and immune evasion and hence, it will be interesting to observe the 
effects of Afatinib on PDAC immune evasion. 
 Another study has suggested the role of tumor microenvironment in the 
acquisition of resistance to Afatinib treatment in NCLCs through HGF secretion [243]. 
Several mechanisms have been reported for acquired resistance to Afatinib treatment 
although functional studies are needed to prove a causative relationship with resistance 
and most of them have been elucidated in lung cancer. Some of these resistance 
mechanisms include V843I EGFR mutation and c-MET amplification, enhanced 
IL6R/JAK/STAT signaling and expression of FGFR1. Additionally, increased interference 
with aerobic glycolysis and autophagy are also proposed to be associated with Afatinib 
resistance [228]. A recent study reported acquisition of resistance to EGFR family 
inhibitors by activation of STAT3 and simultaneous upregulation of p-c-MET, p-STAT3, 
CD44, increased autocrine production of EGFR ligand amphiregulin and differential 
activation status of EGFR tyrosine residues as well as downregulation of total and p-
SRC [190]. The results were majorly cell line based, and further studies are needed to 
elucidate the mechanism behind Afatinib resistance. 
 Afatinib is currently under clinical trials examining its usage as neoadjuvant 
therapy. Considering its role against cancer stem cells unlike chemotherapies 
administering Afatinib at an early stage may be an effective therapeutic regimen. The 
recent release of interim results from phase II ASCENT trial in lung cancer are 
encouraging for future studies in this direction. The trial examines Afatinib as the 
standard of care treatment with curative intent for EGFR+ stage III NSCLC 
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(NCT01553942). Neo-adjuvant afatinib achieved a high objective response rate and 
major surgical path responses. 
Additionally, the results also suggest that neoadjuvant Afatinib exceeds feasibility over 
adjuvant Afatinib in stage III patients. An enhanced progression-free survival has also 
been observed although; more data is needed about optimal strategy for stage III 
EGFR+ pts [244]. These studies provide a case for testing Afatinib in the neoadjuvant 
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